Atlatl Advisers LLC lowered its position in Lumentum Holdings Inc. (NASDAQ:LITE – Free Report) by 14.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,815 shares of the technology company’s stock after selling 834 shares during the period. Atlatl Advisers LLC’s holdings in Lumentum were worth $4,677,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Red Spruce Capital LLC lifted its stake in Lumentum by 0.4% in the 3rd quarter. Red Spruce Capital LLC now owns 3,200 shares of the technology company’s stock worth $3,108,000 after purchasing an additional 12 shares in the last quarter. CYBER HORNET ETFs LLC increased its stake in shares of Lumentum by 7.2% in the 2nd quarter. CYBER HORNET ETFs LLC now owns 209 shares of the technology company’s stock worth $179,000 after acquiring an additional 14 shares during the last quarter. Hilltop National Bank grew its holdings in shares of Lumentum by 26.8% in the second quarter. Hilltop National Bank now owns 71 shares of the technology company’s stock valued at $61,000 after purchasing an additional 15 shares during the period. Sachetta LLC raised its stake in Lumentum by 118.8% during the first quarter. Sachetta LLC now owns 35 shares of the technology company’s stock worth $25,000 after purchasing an additional 19 shares during the period. Finally, Kieckhefer Group LLC raised its stake in shares of Lumentum by 0.8% in the 3rd quarter. Kieckhefer Group LLC now owns 3,191 shares of the technology company’s stock valued at $3,099,000 after acquiring an additional 25 shares during the period. Hedge funds and other institutional investors own 94.05% of the company’s stock.
Insider Transactions at Lumentum In other news, insider Yuen Wupen sold 307 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $945.00, for a total value of $290,115.00. Following the sale, the insider directly owned 108,320 shares in the company, valued at $102,362,400. This represents a 0.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Wajid Ali sold 24,542 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $1,048.50, for a total value of $25,732,287.00. Following the completion of the sale, the chief financial officer directly owned 75,074 shares in the company, valued at approximately $78,715,089. The trade was a 24.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 94,496 shares of company stock worth $85,978,498. 0.28% of the stock is owned by insiders.
Analyst Upgrades and Downgrades Several equities analysts recently issued reports on LITE shares. Stifel Nicolaus increased their target price on Lumentum from $1,100.00 to $1,232.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Deutsche Bank Aktiengesellschaft began coverage on Lumentum in a research report on Monday, August 31st. They issued a “buy” rating and a $1,200.00 target price for the company. Raymond James Financial reiterated an “outperform” rating and set a $1,036.00 price target on shares of Lumentum in a research note on Wednesday, August 12th. Needham & Company LLC reissued a “buy” rating and set a $1,040.00 price target on shares of Lumentum in a research report on Wednesday, August 12th. Finally, Evercore assumed coverage on shares of Lumentum in a research note on Monday, August 31st. They issued an “outperform” rating and a $1,100.00 price objective for the company. Sixteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,080.83. Get Our Latest Stock Analysis on LITE
Trending Headlines about Lumentum Here are the key news stories impacting Lumentum this week:
Positive Sentiment: Jefferies reportedly raised its price target on Lumentum to $1,250, signaling continued confidence in the company’s AI-optics growth prospects. Lumentum stock rises pre-market; Jefferies lifts target to USD 1,250 Positive Sentiment: Brown Advisory identified Lumentum as an opportunity within AI infrastructure, reflecting institutional support for the company’s exposure to optical components used in data centers. Management has also highlighted strong AI demand through early 2029. Brown Advisory Sees AI Infrastructure Opportunity in Lumentum Holdings Inc. (LITE) Neutral Sentiment: Investors are looking ahead to Lumentum’s fiscal first-quarter update on November 4. The company has guided revenue above the prior quarter, while its latest reported quarter exceeded analyst expectations for both earnings and revenue, creating a potentially important catalyst but also raising expectations. Negative Sentiment: Lumentum shares have fallen sharply over the past week as investors reduced exposure to AI-optics stocks following a hotter-than-expected September inflation report. Higher interest-rate concerns are weighing particularly heavily on high-growth technology valuations. Lumentum Holdings (LITE) Fell In The AI Optics Selloff, Is It Still Undervalued? Negative Sentiment: The broader technology selloff has spread across optical-networking peers, including Coherent and Applied Optoelectronics, suggesting the recent weakness is driven more by sector-wide positioning and valuation concerns than by a new company-specific setback. Optics Stocks Tumble as Tech Selloff Deepens Ahead of Earnings Negative Sentiment: Lumentum’s CFO reportedly sold approximately $25.7 million of stock ahead of earnings. Although insider selling does not necessarily indicate deteriorating fundamentals, the timing may add to investor caution. Lumentum Slips Off Its $1,143 Peak as CFO Sells $25.7 Million Ahead of Earnings Lumentum Trading Up 0.5% NASDAQ LITE opened at $756.17 on Friday. The firm’s fifty day moving average price is $924.34 and its 200 day moving average price is $877.75. Lumentum Holdings Inc. has a 12 month low of $173.73 and a 12 month high of $1,143.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.68 and a quick ratio of 1.40. The company has a market capitalization of $68.50 billion, a price-to-earnings ratio of -9.20 and a beta of 1.53.
Lumentum (NASDAQ:LITE – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The technology company reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.26. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $987.70 million. Lumentum had a positive return on equity of 26.34% and a negative net margin of 230.15%. The firm’s quarterly revenue was up 109.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.88 EPS. Lumentum has set its Q1 2027 guidance at 4.050-4.350 EPS. On average, sell-side analysts expect that Lumentum Holdings Inc. will post 19.79 earnings per share for the current fiscal year.
Lumentum Profile (Free Report)
Lumentum Holdings Inc is a technology company that designs and manufactures optical and photonic products for communications networks, industrial applications, and consumer electronics. Its portfolio includes optical components, modules, and subsystems used in fiber-optic networks, data centers, cloud computing infrastructure, telecommunications equipment, and high-speed connectivity systems.
The company also develops laser products for applications such as industrial processing, sensing, three-dimensional imaging, and other specialized commercial and consumer uses.
Featured Stories Five stocks we like better than Lumentum Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Lumentum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumentum and related companies with MarketBeat.com's FREE daily email newsletter.
Ensign has been sued for securities fraud after its stock price fell following reports alleging that the company concealed patient neglect, understaffing, manipulated quality and staffing data, improper billing, and an administrator-license rental scheme.
New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc. (NASDAQ: ENSG) and certain of the company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.
If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.
Key Details of the Ensign ($ENSG) Class Action:
Lead Plaintiff Deadline: December 7, 2026Alleged Misconduct: Securities fraud alleging Ensign misrepresented that its business model relied on patient neglect, understaffing, manipulated quality and staffing data, improper billing, and an administrator-license rental scheme.Largest Alleged Stock Drop: June 8, 2026 – 8.15%Court: U.S. District Court for the Central District of CaliforniaAction: Contact BFA Law to discuss your rightsInvestors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ensign securities. The class action is pending in the U.S. District Court for the Central District of California. It is captioned Perusek v. The Ensign Group, Inc., et al., No. 8:26-cv-02963.
Why is Ensign Being Sued for Securities Fraud?
Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through affiliated providers. The company relies heavily on Medicare and Medicaid reimbursements, making patient care, staffing, billing, and regulatory compliance central to its business model.
According to the complaint, Ensign represented that quality patient care was central to its business, described its clinical outcomes and CMS ratings, and characterized regulatory and compliance risks as contingencies.
As alleged, Defendants concealed systematic understaffing and patient neglect, manipulated reported quality and staffing data, engaged in improper Medicare and Medicaid billing and upcoding, and used licensed administrators who did not actually manage certain facilities.
Why did Ensign's Stock Drop?
On June 8, 2026, Hunterbrook Media published "Ensign: The Nursing Home Empire Built on Fatal Neglect," based on a five-month investigation. The report alleged that Ensign acquired distressed nursing facilities, reduced registered-nurse and other skilled-care hours, used self-reported data to improve quality ratings, and generated profits by providing less care than residents required despite receiving public funds based on patient acuity.
On this news, the price of Ensign stock fell $13.88 per share, or 8.15%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.
On June 11, 2026, Muddy Waters Research published "Ensign: Deceiving the Government at Estimated ~20% of Facilities." The report alleged that Ensign used licensed administrators who were seldom present and did not actually manage certain facilities, while unlicensed operators handled day-to-day operations. Muddy Waters estimated that the alleged practices existed at approximately 20% of Ensign's skilled nursing facilities and could expose Ensign to significant sanctions, slower growth, and reduced margins.
On this news, the price of Ensign stock fell $4.52 per share, or 2.98%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.
On June 18, 2026, Hunterbrook published a follow-up report, "New: Patients Hungry in Ensign Facilities," alleging additional firsthand evidence of resident hunger, inadequate food and supplies, payroll and staffing-data falsification, understaffing, and employees working above their license levels.
On this news, the price of Ensign stock fell $2.19 per share, or 1.4%, to close at $153.65 per share on June 18, 2026.
Click here for more information: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.
What Can You Do?
If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
AppLovin has been sued for securities fraud after its stock plummeted 20% because AppLovin allegedly misrepresented the strength, viability, and development of its AI-based business model and products.
New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against AppLovin Corporation (NASDAQ: APP) and certain of the company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.
If you invested in AppLovin, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/applovin-class-action-lawsuit.
Key Details of the AppLovin ($APP) Class Action:
Lead Plaintiff Deadline: November 16, 2026Alleged Misconduct: Securities fraud alleging AppLovin misrepresented the strength, viability, and development of its AI-based business model and products Largest Alleged Stock Drop: August 5, 2026 – 20% Stock DropCourt: U.S. District Court for the Northern District of CaliforniaAction: Contact BFA Law to discuss your rightsInvestors have until November 16, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in AppLovin securities. The class action is pending in the U.S. District Court for the Northern District of California. It is captioned Talbot v. AppLovin Corp., et al., No. 26-cv-10584.
Why is AppLovin Being Sued for Securities Fraud?
AppLovin is an advertising solutions company. AppLovin claims its advertising products use artificial intelligence ("AI") models, among other things, to more effectively match advertisers to prospective customers.
According to the complaint, AppLovin touted the purported strength of the company's AI models as a major driver of the company's growth, telling investors that AppLovin was "constantly improving" its models and that "we don't really see a reason why that's going to slow down."
As alleged, the company's new generative AI video tool in its AppLovin Ads platform experienced significant development delays, which stymied improvements to AppLovin's AI model.
Why did AppLovin's Stock Drop?
On July 13, 2026, a Bank of America Securities analyst published a note stating that "AppLovin's eCommerce footprint expanded at a slower pace in June" and "[w]eekly data has not shown a clear uptick since AppLovin [Ads] opened to all eComm advertisers on 6/22, suggesting a muted GA start." Accordingly, Bank of America Securities lowered its estimate for AppLovin's annual revenue.
On this news, AppLovin's stock price dropped $64.13 per share, or 12.6%, from a closing price of $506.80 per share on July 10, 2026, to a closing price of $442.85 per share on July 13, 2026.
Then, on August 5, 2026, after the market closed, AppLovin announced that it missed consensus estimates for quarterly revenue, delivering $1.92 billion of revenue against consensus estimates of $1.94 billion. Defendants attributed the miss, in part, to delays in the roll out of AppLovin Ads' generative AI video creation tool, which led to lower-than-expected AppLovin Ads revenue and hampered AppLovin's AI "model performance[.]"
On this news, AppLovin's stock price dropped $82.13 per share, or 19.6%, from a closing price of $417.80 per share on August 5, 2026, to a closing price of $335.67 per share on August 6, 2026.
Click here for more information: https://www.bfalaw.com/cases/applovin-class-action-lawsuit.
What Can You Do?
If you invested in AppLovin, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
While many will tell you the biggest bottleneck in AI is the chip supply, I actually believe it's electricity. Because of this, Bloom Energy (BE -11.24%) will be the biggest winner of the AI power crunch for one reason in particular: The company's speed to power is top-notch.
AI hyperscalers and their data centers cannot wait years for utility hookups. Bloom's solid oxide fuel cells help businesses avoid this wait. The company's systems can bring a data center online in about three months and don't require grid connectivity. This is a massive advantage, and customers are coming on board at record scale.
$193.30-$24.47 (-11.24%)
NYSE · As of 4:00 PM ET 10/23/26
The demand behind Bloom is quickly converting to revenue, as the company crossed $1 billion in the second quarter, a 166% year-over-year increase. Bloom's balance sheet is improving rapidly, with the company boasting about $2.7 billion in cash.
Management raised its full-year guidance to reflect a substantial increase in revenue, with a range of $3.9 billion to $4.2 billion. That's just about double what the company did in 2025.
Image source: The Motley Fool.
All this momentum means the stock isn't cheap. Shares have skyrocketed more than 150% year to date. The stock is trading at a whopping 357 times trailing earnings. For long-term investors, the premium is justified by the ever-improving balance sheet and incessant demand for fast power. We're still early on in the AI and data center days. Bloom's systems will be needed for years to come.
Catie Hogan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bloom Energy. The Motley Fool has a disclosure policy.
BFA Law is investigating the announced $212.00 per share merger in which Roger Penske and Mistui & Co., Ltd. are set to acquire Penske Automotive Group, Inc.; current shareholders are notified to contact the firm.
New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it is investigating the going private merger whereby Penske Automotive Group, Inc. (NYSE: PAG) is being taken private by its controlling stockholders, Roger Penske and Mitsui & Co., Ltd. Penske is incorporated in Delaware.
If you are a current shareholder of Penske, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/penske-investigation.
Key Details of the Penske ($PAG) Investigation:
Investigation Overview: Breaches of Fiduciary Duty in connection with the merger under which Roger Penske and Mitsui will acquire the public stock of Penske for $212.00 per shareAction: Contact BFA Law to discuss your rightsWhy is the Penske Transaction being Investigated?
Penske Automotive Group, Inc. ("Penske") is a company that is controlled by two majority stockholders—Roger Penske (via "Penske Corporation") and Mitsui & Co., Ltd. ("Mitsui"). Those two stockholders alone control 72.3% of the company's voting power.
Penske's initial disclosures have reported that the company utilized a special committee to evaluate the merger and that the merger is conditioned on the approval of the public stockholders at an upcoming stockholder vote. Penske has not yet disclosed the full details of the process that resulted in the merger, and key questions about whether those protective mechanisms were effective remain unanswered.
BFA is investigating whether the terms of the merger comply with Delaware law, including whether the $212.00 per share price is a fair price for the public stockholders' shares of Penske stock.
Click here for more information:
https://www.bfalaw.com/cases/penske-investigation
What Can You Do?
If you are a current holder of Penske stock, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases/penske-investigation
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/penske-investigation
Attorney advertising. Past results do not guarantee future outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320508
Source: Bleichmar Fonti & Auld
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
BFA Law is investigating whether Six Flags Entertainment Corporation committed securities fraud relating to statements about its focus on safety, maintenance, and ride reliability.
New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Six Flags Entertainment Corporation (NYSE: FUN) for potential securities fraud after its significant stock drop.
If you invested in Six Flags securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/six-flags-class-action-lawsuit.
Key Details of the Six Flags ($FUN) Class Action Investigation:
Investigation Overview: Securities fraud relating to Six Flags' statements about its focus on safety, maintenance, and ride reliability.Stock Decline: October 13, 2026 – 14.4% Stock DropAction: Contact BFA Law to discuss your rightsWhy is Six Flags Being Investigated for Securities Fraud?
Six Flags is the largest regional amusement resort operator in North America, with 20 amusement parks, 14 water parks and nine resort properties in the U.S., Canada, and Mexico.
BFA is investigating whether Six Flags misled investors about its focus on safety, maintenance, and ride reliability.
Why did Six Flags' Stock Drop?
On October 12-13, 2026, various news outlets reported that a man died and several others were injured aboard Six Flags' Goliath roller coaster in Georgia. After the fatal incident, Six Flags announced the temporary closure of 10 roller coasters, including Goliath, across various amusement parks.
Following the news, Six Flags shares fell approximately 14.4% on October 13, 2026.
Click here for more information: https://www.bfalaw.com/cases/six-flags-class-action-lawsuit.
What Can You Do?
If you invested in Six Flags securities, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "Super Lawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Fluence has been sued for securities fraud after its stock plummeted 35% because Fluence allegedly misrepresented the status of its manufacturing operations and ability to achieve its revenue and EBITDA guidance.
New York, New York--(Newsfile Corp. - October 24, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Fluence Energy, Inc. (NASDAQ:FLNC) and certain of the company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.
If you invested in Fluence, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/fluence-class-action-lawsuit.
Key Details of the Fluence ($FLNC) Class Action:
Lead Plaintiff Deadline: November 27, 2026Alleged Misconduct: Securities fraud alleging Fluence misrepresented the status of its manufacturing operations and ability to achieve its revenue and EBITDA guidance Largest Alleged Stock Drop: February 5, 2026 – 34.6% Stock DropCourt: U.S. District Court for the Southern District of New YorkAction: Contact BFA Law to discuss your rightsInvestors have until November 27, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Fluence securities. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Hatweek v. Fluence Energy, Inc. et al., No. 26-cv-8475.
Why is Fluence Being Sued for Securities Fraud?
Fluence is a provider of energy storage systems and optimization software for the renewable energy and energy storage industries.
According to the complaint, Fluence provided record breaking fiscal year 2026 revenue guidance and significantly increased adjusted EBITA guidance based on its purported ability to capitalize on surging demand for data centers. Fluence assured investors that it had contracted with multiple key production facilities to fulfill demand.
As alleged, Defendants failed to disclose that several new contract manufacturing facilities were not completed, not operational, and/or not capable of producing at the volumes Fluence's guidance provided.
Why did Fluence's Stock Drop?
On February 4, 2026, Fluence reported a net loss of $62.6 million and a GAAP gross profit margin of 4.9%, a 6.5% decline year over year, due to "additional estimated costs on two projects" located outside the U.S.
On this news, Fluence's stock dropped $10.04 per share, or 34.6%, from a closing price of $28.99 per share on February 4, 2026, to $18.95 per share on February 5, 2026.
On August 5, 2026, Fluence reported "weaker than expected revenue" and slashed revenue and adjusted EBITDA guidance because of "production delays at new contract manufacturing facilities."
On this news, Fluence's stock dropped $1.02 per share, or 7.2%, from a closing price of $14.23 per share on August 5, 2026, to $13.21 per share on August 6, 2026.
On September 16, 2026, Fluence issued a mid-quarter guidance update and further slashed revenue and adjusted EBITDA guidance because of "delays in the ramp-up of our contract manufacturing facility."
On this news, Fluence's stock dropped $1.39 per share, or 15.4%, from a closing price of $9.05 per share on September 16, 2026, to $7.66 per share on September 17, 2026.
Click here for more information: https://www.bfalaw.com/cases/fluence-class-action-lawsuit.
What Can You Do?
If you invested in Fluence, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360, and "SuperLawyers" by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."
BFA's notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
Sigma Lithium Corp (TSX-V:SGML, NASDAQ:SGML, ASX:SAU) has agreed with Synergy Capital to push back the maturity of its US$100 million senior secured debt by six months, to June 2027 from December 2026.
The interest rate on the facility is unchanged at SOFR plus 6.95% per year, according to a statement from the company.
The extension defers the final repayment requirement due in December and lengthens 93% of the Brazil-focused lithium producer’s debt profile to June 2027, giving it more financial flexibility as it executes its plans.
The new agreement keeps the same basic terms and default triggers as the original December 2022 deal.
The extra time comes as Sigma ramps up output following the restart of operations. The company resumed work on October 5 after Brazil’s Federal Superior Court reinstated all of its environmental licenses, and it produced 7,090 tonnes of lithium oxide concentrate between October 5 and October 21.
Sigma maintains its target of scaling annualized production of lithium oxide concentrate to 330,000 tonnes by the end of 2027, supported by existing capacity at its Cleantech Industrial Plant and its recycling and reprocessing circuits.
The deal follows a period of deleveraging. Sigma has repaid more than US$90 million in debt since the second quarter of 2024 through cash generation, cutting total debt by about 40% over two years to US$125 million as of October 21.
“The six-month extension provides additional time to continue ramping up production ahead of the new maturity date,” Sigma CEO Ana Cabral said in a statement.
“Together with our low costs and current lithium pricing levels, we expect to regain operational cash flow momentum,” Cabral added.
Sigma said it supports 19,000 jobs and about 80,000 family members in Brazil’s Vale do Jequitinhonha region, where it operates across 12 municipalities.
The company will report third-quarter 2026 production, sales, realized prices, costs and cash by November 13.
Shares of Mexican hard discount grocer BBB Foods (TBBB +1.56%) soared 14% higher Thursday as of 1 p.m. ET after the company reported second-quarter earnings after market close yesterday. While the company reported a larger-than-expected net loss, its sales rose 39%, easily surpassing Wall Street's top-line estimates and prompting today's share price rise.
TBBB BBB Foods$58.50+$0.90 (+1.56%)
NYSE · As of 4:00 PM ET 10/23/26
Home to 3,624 Tiendas 3B stores (which stands for Bueno, Bonito, and Barato, and translates to "good, nice, and cheap"), BBB Foods remains in hypergrowth mode, so the market is willing to look past a slight earnings miss in favor of blistering sales growth.
Altogether, it was a great quarter for the company as BBB Foods delivered:
revenue growth of 39% a same-store sales increase of 20% adjusted EBITDA (non-including stock-based compensation) growth of 44% 155 new store openings to 3,624 total first-half of 2026 cash from operations growth of 119%
Image source: Getty Images.
Management believes Mexico can support "at least" 14,000 Tiendas 3B stores, so BBB could theoretically quadruple its store count over the long term. The company's Q2 results show that it is laser-focused on doing just that. Most importantly for investors, despite opening nearly 600 stores over the last year -- growing its share count by roughly 20% -- BBB is self-funding this incredible growth thanks to its booming cash from operations.
BBB Foods focuses on small-footprint locations, high-volume sales of a limited assortment, a private-label emphasis, and a low-cost model, and is often considered the "Aldi" of Mexico. With only 3% of grocery sales in Mexico coming from hard-discount grocers -- compared to 38% in Poland, 24% in Germany, and double digits in most developed countries -- the white space in front of BBB Foods is an incredible opportunity for the company and investors alike.
Currently, TBBB stock trades at somewhere around 30 times forward cash from operations, which isn't outrageous considering the company's incredible growth rates. I wouldn't go "all-in" on the stock after it has risen nearly 100% over the last year, but I'll be looking to add to my shares on any dip.
Trader Joe's is one of the most popular supermarket chains in the U.S., and the company has been growing steadily since it opened its first store in California in 1967.
The brand has developed a cult-like following thanks to its low prices, private-label strategy, focus on core products, and a central-kitchen model in which goods like meat, seafood, and bread are prepared off-site rather than in the store.
Trader Joe's is widely believed to be the leader in sales per square foot among national supermarket chains, pulling in an estimated annual sales of $1,750-$2,400 per square foot, which is double that of Whole Foods and about four times that of the average supermarket chain.
Unfortunately, for investors, Trader Joe's isn't public. It's owned by Aldi Nord, one of the two privately held companies that emerged from the split between the brothers who founded Aldi.
While you can't invest in Aldi or Trader Joe's, there is a rapidly growing Mexican chain that resembles both of those leading discount banners: BBB Foods (TBBB +1.56%).
Image source: BBB Foods.
What is BBB Foods?
BBB Foods is the parent of the grocery retail chain, Tiendas 3B, which stands for "Bueno, Bonito y Barato," or "Good, Nice and Affordable."
BBB Foods has delivered strong results as both a business and a stock since it went public in 2024. As you can see from the chart below, the stock has nearly tripled since then.
TBBB data by YCharts
Since going public, the company has delivered phenomenal growth both on a same-store basis and by rapidly expanding its footprint, which reached more than 3,600 stores in its second quarter.
Same-store sales have regularly been in the double digits every quarter since it went public, and it seems to be winning using the same business model that has made Trader Joe's and Aldi so successful.
The company's stores are small at just 3,000-4,500 square feet, compared to 10,000-15,000 square feet for a typical Trader Joe's, which is still much smaller than the average Whole Foods or Kroger store.
Like Trader Joe's, Tiendas 3B has a heavy focus on private-label products, which account for more than 58% of its merchandise sales. It also offers high-quality private-label alternatives of specialty products like granolas and spreads.
Similar to TJ's, Tiendas 3B strictly limits the number of stock-keeping units it carries, typically having one name brand per category and its own 3B brand. Finally, it also leans into the "treasure hunt" effect by stocking limited-time products that a typical discount chain wouldn't carry.
Overall, the brand may be more similar to Aldi because it's more of a no-frills neighborhood store targeting a working-class demographic, but it shares commonalities with both chains.
TBBB BBB Foods$58.50+$0.90 (+1.56%)
NYSE · As of 4:00 PM ET 10/23/26
Is BBB Foods a buy?
Tiendas 3B just jumped 16% on Thursday after the company reported that same-store sales growth accelerated to 20% in the second quarter, which, along with its aggressive expansion, drove revenue to 26 billion pesos, or roughly $1.5 billion, up 38.7%.
The company's margins are still low, with an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin, which excludes share-based compensation, of 6.1%. Grocery chains typically operate on narrow margins, and 3B expects to grow over time as it opens new stores, improves operational efficiency, and focuses on its customer value proposition.
The company added 155 new stores in the quarter, to reach 3,624, showing it's expanding its base by roughly 16% a year, and it plans to quadruple its store base to at least 14,000 over the long term.
A lot of retail businesses would struggle with cannibalization when growing that fast, but 3B is going in the opposite direction with comparable sales soaring, and that's a strong testament to demand for the brand.
Additionally, its price-to-sales ratio of 1 looks like a fair price to pay for a fast-growing grocery chain. After the latest report, BBB Foods looks like a strong buy.
word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word word
Sami Gabriel Khouri, a director at BBB Foods Inc. (TBBB +1.56%), disclosed a non-discretionary disposition of 14,101 Class A Common Shares on August 7, according to an SEC Form 4 filing.
Transaction summaryMetricValueTransaction value~$573,500Shares sold14,101Post-transaction shares (total)~3.6 millionPost-transaction shares (directly held)~196,000Post-transaction shares (indirectly held)~3.4 millionTransaction value based on SEC Form 4 weighted average sale price ($40.67); post-transaction value based on the August 7 market close ($40.80).
Key questionsWhat was the primary driver of this transaction?
The disposition was entirely non-discretionary, executed by the company to cover tax withholding obligations triggered by the exercise of 14,101 stock options. These options were fully vested and originally exercisable for Class C shares before their automatic conversion to Class A shares on the transaction date.How much equity does Sami Gabriel Khouri retain in the company?
Following this transaction, the director maintains a core position of about 3.6 million shares, representing approximately 3% ownership of the company. The vast majority of this stake is held through indirect ownership structures, while about 196,000 shares are held directly.How has the stock performed leading up to this disclosure?
As of the August 7 transaction date, the company has delivered a one-year return of 60%. While the transaction occurred with the stock priced at $40.67 per share, the non-discretionary nature of the tax withholding means the activity does not reflect an active assessment of the current valuation by the director.Company OverviewMetricValueShare Price (as of market close 2026-08-10)$40.65Market Capitalization$5 billionRevenue (TTM)$83.3 billionNet Income (TTM)-$3.3 billionCompany SnapshotBBB Foods Inc. operates a network of discount grocery retail outlets throughout Mexico, offering customers a comprehensive selection of essential food and beverages, personal care products, household cleaning supplies, coffee, tea, dessert items, and specialized goods for infants and pets, alongside both established brands and private label merchandise.The company generates revenue through retail sales across its discount store network, leveraging a diversified product portfolio that combines well-known national brands with proprietary private label lines and strategically sourced spot products to optimize margins and customer value.BBB Foods serves Mexican consumers seeking affordable grocery and household essentials, with particular emphasis on price-conscious households that prioritize value and convenience in their retail shopping experience.BBB Foods Inc. operates as a significant discount retail grocer in Mexico with substantial scale, managing a network of approximately 29,202 employees and generating $83.3 billion in TTM revenue. The company's competitive positioning centers on its ability to offer a diverse merchandise mix at discount pricing while maintaining operational efficiency across its Mexican retail footprint. Despite current profitability challenges reflected in a TTM net loss of $3.3 billion, the company's substantial revenue base and market presence underscore its significance within the Mexican consumer defensive sector.
What this transaction means for investorsKhouri's shares went to cover taxes on an option exercise, so the sale itself carries no message worth dwelling on, and he keeps roughly 3.6 million shares, about 3% of the company.
Meanwhile, BBB Foods, which runs Mexico's popular Tiendas 3B hard-discount chain, reported just last week that it grew second-quarter revenue 39% to 26 billion pesos, lifted same-store sales 20%, and opened 155 net new stores in a single quarter, reaching more than 3,600. It is expanding aggressively and funding that growth from its own cash flow rather than leaning on debt. Chairman and CEO Anthony Hatoum pointed to results delivered "despite a soft consumer environment in Mexico." The one figure that looks alarming, a net loss, is mostly an accounting artifact, since it stems from non-cash stock-compensation charges and costs tied to a share offering rather than the stores losing money, and cash from operations actually surged.
The real question for this stock is durability, not the loss. BBB is compounding revenue near 40% while the market barely grows, so what shareholders are underwriting is how long it can keep opening stores and taking share before that pace cools.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BBB Foods. The Motley Fool has a disclosure policy.
Juan Pablo Cappello, a director at BBB Foods Inc. (TBBB +1.56%), reported the disposition of 7,660 shares valued at $312,000 on August 7, according to an SEC Form 4 filing.
Transaction summaryMetricValueTransaction value~$312,000Shares sold7,660Post-transaction shares (directly held)97,295Post-transaction value$3.97 millionTransaction value based on SEC Form 4 weighted average sale price ($40.67); post-transaction value based on the August 7 market close ($40.80).
Key questionsWhat was the nature of this transaction?
This was a non-discretionary transaction executed to cover tax obligations associated with the exercise of stock options and does not reflect a change in the director's personal outlook on the company.How did the underlying security structure change?
Footnotes in the filing indicate that the options exercised were originally for Class C Common Shares, which automatically converted into an equal number of Class A Common Shares on August 7.What is the director's remaining equity stake?
Following this disposition, Cappello retains direct ownership of 97,295 Class A Common Shares, representing a total market value of $3.97 million based on the transaction-date market close.Company OverviewMetricValueShare Price (as of market close 2026-08-10)$40.65Market Capitalization$4.7 billionRevenue (TTM)$83.3 billionNet Income (TTM)-$3.3 billionCompany SnapshotBBB Foods Inc. operates a network of discount grocery retail outlets throughout Mexico, offering customers a comprehensive selection of essential food and beverages, personal care products, household cleaning supplies, coffee, tea, dessert items, and specialized goods for infants and pets, alongside both established brands and private label merchandise.The company generates revenue through retail sales across its discount store network, leveraging a diversified product portfolio that combines well-known national brands with proprietary private label lines and strategically sourced spot products to optimize margins and customer value.BBB Foods serves Mexican consumers seeking affordable groceries and household essentials, with particular emphasis on price-conscious households that prioritize value and convenience in their retail shopping.BBB Foods Inc. operates as a significant discount retail grocer in Mexico with substantial scale, managing a network of approximately 29,202 employees and generating $83.3 billion in TTM revenue. The company's competitive positioning centers on its ability to offer a diverse merchandise mix at discount pricing while maintaining operational efficiency across its Mexican retail footprint. Despite current profitability challenges, as reflected in a TTM net loss of $3.3 billion, the company's substantial revenue base and market presence underscore its significance in the Mexican consumer defensive sector.
What this transaction means for investorsCappello is one of a few BBB Foods insiders to have options vest on the same day, with shares sold purely to cover the taxes, and like in those cases, this filing says nothing about how he views the stock, especially given that he holds more than 97,000 shares still.
What's worth a look, however, is what sits beneath the company's fast growth. A big part of BBB's edge is private label. Its Tiendas 3B stores lean heavily on their own brands, which carry better margins than national ones and let the chain undercut rivals on price, and that mix helped widen gross margin even as revenue grew 39% last quarter. The company is opening stores at a breakneck clip, more than 150 in the quarter, and funding it from its own cash. Chairman and CEO Anthony Hatoum noted the results came "despite a soft consumer environment in Mexico." That last phrase is one important thing to consider for long-term investors. BBB appears to be thriving precisely because cash-strapped shoppers are trading down to hard discounters, as has been the case with discount retailers and even pawn shops in the U.S., so a stronger consumer could ease the tailwind, even as a weaker one tests how much lower-income households can spend at all.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BBB Foods. The Motley Fool has a disclosure policy.
Rose Nicole Dominique Reich Sapire, a director at BBB Foods Inc. (TBBB +1.56%), disposed of 4,754 shares of Class A Common Shares on August 7, according to a recent SEC Form 4 filing.
Transaction summaryMetricValueTransaction value~$193,345Shares sold4,754Post-transaction shares (directly held)15,246Post-transaction value$622,036.80Transaction value based on SEC Form 4 weighted average sale price ($40.67); post-transaction value based on the August 7 market close ($40.80).
Key questionsWhat was the specific nature of this transaction?
This was a non-discretionary transaction executed to cover tax withholding obligations associated with the exercise of 4,754 stock options at $9.67 per share; as such, it does not represent a discretionary market sale or reflect the director's personal sentiment regarding the stock.What is the status of the director's remaining equity compensation?
Following this exercise, the director continues to hold 65,520 direct stock options, which are part of a vesting schedule that continues through the fifth anniversary of December 15, 2022.How does the current market valuation compare to the transaction price?
The shares were disposed of at a weighted average price of $40.67, while the stock closed on the August 7 transaction date at $40.80, a period during which the company has seen a 60% one-year total return.What is the scale of the director's total beneficial ownership?
The director's total beneficial ownership stands at 15,246 direct shares of Class A Common Shares, valued at $622,036.80 based on the August 7 market close, representing a 0.01% ownership stake in the $5 billion company.Company OverviewMetricValueShare Price (as of market close 2026-08-10)$40.65Market Capitalization$4.7 billionRevenue (TTM)$83.3 billionNet Income (TTM)-$3.3 billionCompany SnapshotBBB Foods Inc. operates a network of discount grocery retail outlets throughout Mexico, offering customers a comprehensive selection of essential food and beverages, personal care products, household cleaning supplies, coffee, tea, dessert items, and specialized goods for infants and pets, as well as both established brands and private-label merchandise.The company generates revenue through retail sales across its discount store network, leveraging a diversified product portfolio that combines well-known national brands with proprietary private-label lines and strategically sourced spot products to optimize margins and enhance customer value.BBB Foods serves Mexican consumers seeking affordable groceries and household essentials, with particular emphasis on price-conscious households that prioritize value and convenience in their retail shopping.BBB Foods Inc. operates as a significant discount retail grocer in Mexico with substantial scale, managing a network of approximately 29,202 employees and generating $83.3 billion in TTM revenue. The company's competitive positioning centers on its ability to offer a diverse merchandise mix at discount pricing while maintaining operational efficiency across its Mexican retail footprint. Despite current profitability challenges, as reflected in a TTM net loss of $3.3 billion, the company’s substantial revenue base and market presence underscore its significance in the Mexican consumer defensive sector.
What this transaction means for investorsReich Sapire, like fellow directors on the same day, had options vest, and she gave up a few thousand shares to taxes. There’s not much there for long-term investors to dwell on, but that doesn’t mean there’s not a lot worth assessing here. BBB Foods is on a tear in Mexico, opening up stores rapidly and hitting new record stock highs.
Management estimates the market could support up to about 12,000 stores, vastly more than the roughly 3,624 Tiendas 3B locations open today. So even after growing revenue 39% last quarter and opening 155 stores in three months, BBB is arguably still early in filling out its home market. On the call, Chairman and CEO Anthony Hatoum said, “We are but at the beginning of our journey,” and the company noted it sees no real estate constraints to opening stores at its current pace. Its negative-working-capital model means each new store helps fund the next.
The long runway is the bull case and the thing to monitor at once. A path from roughly 3,600 stores toward five figures is enormous, but it rests on BBB executing that build-out for years without the store economics or same-store trend faltering along the way.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BBB Foods. The Motley Fool has a disclosure policy.
Tiendas 3B delivered another exceptional quarter, with same-store sales up ~20% and revenue growth accelerating to 38.7% year-over-year. TBBB continues aggressive expansion, opening 155 new stores in Q2 and maintaining strong traffic despite low food inflation and broader retail weakness. Adjusted EBITDA grew 43.8% to ~6.1% margin, but share count dilution from SBC remains a concern, potentially reaching ~142 million shares by FY 2030.
Director Rose Nicole Dominique Reich Sapire sold 7,623 shares of BBB Foods Inc. (TBBB +1.56%) on September 9, 2026. SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)7,623Transaction value~$389,000Post-transaction shares (directly held)0Post-transaction value$0Transaction value based on SEC Form 4 weighted average sale price ($51.00); post-transaction value based on Sept. 09, 2026 market close ($51.66).
Key questionsWhat was the scale of this transaction relative to the insider's total direct position?
The sale of 7,623 shares accounted for the entirety of the director's reported direct equity stake in the company.How has the stock performed in the year leading up to this transaction?
Shares of BBB Foods returned 98% in the one-year period concluding on the Sept. 9, 2026 transaction date.What is the current equity exposure following this filing?
The director now holds zero direct Class A Common Shares, and no derivative securities or indirect holdings were disclosed in this filing.What are the reported financial fundamentals for the company?
The company reported trailing twelve-month revenue of MXN 91.1 billion and a net income loss of MXN 3.4 billion as of the latest reporting period.Company OverviewMetricValueShare Price (as of market close 2026-09-11)$50.46Market Capitalization$6.1 billionRevenue (TTM)MXN 91.1 billionNet Income (TTM)-MXN 3.4 billionCompany SnapshotBBB Foods Inc. operates a comprehensive network of grocery retail outlets throughout Mexico, offering a diverse product portfolio that includes essential food and beverages, personal care and household cleaning products, coffee, tea, dessert items, and specialized goods for infants and pets, alongside both established brand names and proprietary private label merchandise.The company generates revenue through a discount retail model that combines high-volume sales of everyday consumer staples with strategically sourced specialty products, leveraging its extensive distribution network and private label offerings to maintain competitive pricing and margin optimization.BBB Foods Inc. primarily serves Mexican consumers seeking value-oriented grocery shopping, with its customer base spanning middle and lower-income households that prioritize affordability and product variety in their everyday purchasing decisions.BBB Foods Inc. operates as a significant discount grocery retailer in Mexico with a workforce of 29,202 employees managing a substantial retail footprint. The company's strategic positioning in the consumer defensive sector reflects its focus on essential goods with stable demand characteristics. Despite current net income pressures, the company's substantial revenue base of MXN 91.1 billion TTM demonstrates its scale and market presence within Mexico's retail landscape.
What this transaction means for investorsNicole Reich's liquidation of her entire BBB Foods position is notable and may leave investors confused.
Indeed, the consumer staples stock's 98% gain may have made it a great time to take some profits. Still, the company, often called the "Aldi of Mexico," has driven rapid growth using its ultra-low cost, limited selection model that relies on private-label goods.
TBBB BBB Foods$58.50+$0.90 (+1.56%)
NYSE · As of 4:00 PM ET 10/23/26
However, the financials indicate that the stock is closer to being a buy than a sell. In the first half of 2026, revenue of 48.9 billion pesos ($2.9 billion) rose by 36% from year-ago levels.
Also, despite the losses in recent quarters, it was profitable as recently as 2024. The company has invested heavily to support its growth, indicating that investment should benefit BBB in the long run.
As for Reich's sale, investors are left to speculate, though it is possible the sale had nothing to do with the company's performance. Nonetheless, given BBB’s growth and the success of its business model, the liquidation of her position is probably not an event that should influence investors.
Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BBB Foods. The Motley Fool has a disclosure policy.
BBB Foods (NYSE: TBBB - Get Free Report) and Chefs' Warehouse (NASDAQ: CHEF - Get Free Report) are both mid-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares BBB Foods
Shares of BBB Foods Inc. (NYSE:TBBB – Get Free Report) hit a new 52-week high on Monday. The stock traded as high as $54.00 and last traded at $53.9380, with a volume of 249000 shares. The stock had previously closed at $52.65.
Wall Street Analyst Weigh In Several brokerages have recently issued reports on TBBB. UBS Group lifted their price target on BBB Foods from $51.00 to $58.00 and gave the company a “buy” rating in a report on Friday, August 28th. Zacks Research raised shares of BBB Foods from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of BBB Foods in a research note on Monday, September 21st. JPMorgan Chase & Co. boosted their target price on shares of BBB Foods from $48.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, September 10th. Finally, Citigroup restated a “buy” rating on shares of BBB Foods in a research note on Monday, September 14th. Seven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BBB Foods currently has a consensus rating of “Moderate Buy” and an average price target of $50.50.
Read Our Latest Report on TBBB
BBB Foods Price Performance The company has a debt-to-equity ratio of 2.16, a current ratio of 0.68 and a quick ratio of 0.44. The stock’s 50 day moving average price is $48.73 and its two-hundred day moving average price is $42.04. The firm has a market capitalization of $6.42 billion, a price-to-earnings ratio of -33.64 and a beta of 0.02. BBB Foods (NYSE:TBBB – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The firm had revenue of $1.49 billion during the quarter, compared to analyst estimates of $1.42 billion. BBB Foods had a negative net margin of 3.68% and a negative return on equity of 72.47%. On average, equities research analysts anticipate that BBB Foods Inc. will post -0.62 EPS for the current year.
Insider Buying and Selling at BBB Foods In related news, Director Sapire Rose Nicole Domin Reich sold 7,623 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $51.00, for a total transaction of $388,773.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Institutional Investors Weigh In On BBB Foods Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. acquired a new stake in shares of BBB Foods during the 1st quarter worth approximately $65,967,000. Wasatch Advisors LP increased its stake in BBB Foods by 20.3% in the first quarter. Wasatch Advisors LP now owns 4,099,825 shares of the company’s stock valued at $145,011,000 after acquiring an additional 690,544 shares during the period. Carmignac Gestion lifted its stake in BBB Foods by 526.5% during the second quarter. Carmignac Gestion now owns 670,106 shares of the company’s stock worth $27,917,000 after purchasing an additional 563,141 shares during the period. The Manufacturers Life Insurance Company acquired a new position in shares of BBB Foods in the 2nd quarter worth approximately $10,630,000. Finally, Ancient Art L.P. boosted its stake in BBB Foods by 183.1% in the 4th quarter. Ancient Art L.P. now owns 391,637 shares of the company’s stock valued at $13,077,000 after buying an additional 253,320 shares in the last quarter. 8.42% of the stock is owned by institutional investors.
BBB Foods Company Profile (Get Free Report)
BBB Foods Inc operates Tiendas 3B, a hard-discount grocery retail chain in Mexico. The company serves value-conscious consumers through small-format neighborhood stores focused on convenient locations, a streamlined shopping experience and everyday low prices.
Tiendas 3B stores offer a selection of essential grocery and household products, including packaged foods, beverages, personal-care items, cleaning supplies and other daily necessities. The assortment combines private-label merchandise with branded products, and certain locations also carry fresh or perishable goods.
BBB Foods was established to develop the hard-discount retail model in Mexico and has expanded its store network across the country, primarily in urban and suburban communities.
Recommended Stories Five stocks we like better than BBB Foods Rivian Escapes the EV Graveyard—But Can It Stay Alive? Allient’s Data Center and Defense Momentum Is Raising the Stakes Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI Lamb Weston’s Turnaround Is Starting to Look Real Receive News & Ratings for BBB Foods Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BBB Foods and related companies with MarketBeat.com's FREE daily email newsletter.
On October 09, 2026, BBB Foods Inc TBBB shares rose 4.8% to $55.59. This surge comes amidst a 52-week range of $24.19 to $55.87, reflecting a remarkable year for the stock.
GF Value™ verdict: Current price of $55.59 is 32.8% overvalued compared to GF Value of $41.85. GF Score™: 35/100, indicating below-average performance in key areas. Most notable signal: Insiders sold $0.8M worth of shares over the past 12 months, with no buying activity. Is TBBB Overvalued or Undervalued? Currently, BBB Foods Inc is trading at $55.59, which is significantly above the GF Value™ estimate of $41.85. This indicates that the stock is 32.8% overvalued, suggesting a lack of margin of safety for potential investors. The GF Valuation label categorizes the stock as significantly overvalued, which highlights the risks associated with investing at this price level. GF Value™ is GuruFocus' proprietary estimate of a stock's intrinsic value, derived from historical trading multiples, past growth, and projections for future performance.
For a loss-making company like TBBB, traditional earnings-based valuation metrics such as the Price-to-Earnings (P/E) ratio do not apply effectively. Instead, a Price-to-Sales (P/S) analysis may provide a clearer picture of valuation, especially given TBBB's status as an unprofitable and cash-flow-negative entity.
How Does TBBB's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 311.4x 139.6x The current P/E ratio of 311.4x is well above the 5-year median P/E of 139.6x, indicating that TBBB is trading at a substantially higher valuation compared to its historical averages. This analysis aligns with the GF Value™ verdict of the stock being overvalued, reinforcing the caution investors should exercise in considering entry points at this level.
What Does TBBB's GF Score™ Tell Us? The GF Score™ measures a company's overall financial health and growth potential, considering factors like financial strength, profitability, growth, valuation, and momentum. TBBB has a GF Score™ of 35/100, with its strongest sub-rank being Valuation at 5/10, while the weakest areas are Growth and Momentum, both at 0/10.
Metric Rating GF Score™ 35/100 Financial Strength 5/10 Profitability 3/10 Growth 0/10 Valuation 5/10 Momentum 0/10 The overall score of 35 indicates that TBBB is performing below average in key financial metrics. The Valuation rank suggests some relative strength, yet the low Growth and Momentum ranks highlight significant weaknesses in the company's ability to generate future growth and maintain positive price trends.
What Are Gurus and Insiders Doing with TBBB? Currently, 7 gurus hold shares of TBBB, with 4 increasing their positions and 2 trimming back in recent quarters. This indicates a mixed sentiment among institutional investors. However, it is crucial to note that insiders have sold $0.8 million worth of shares over the past 12 months, with no insider buying activity during the same period. This pattern of insider selling raises concerns about the confidence of those closest to the company in its future performance.
What This Means for Investors In conclusion, BBB Foods Inc TBBB appears to be overvalued at its current price of $55.59, especially when compared to the GF Value™ estimate of $41.85. The combination of a high P/E ratio and concerning insider selling signals suggests caution for potential investors. For further details and analysis, visit the BBB Foods Inc (TBBB) stock page.
Frequently Asked Questions What is TBBB's GF Score™?
TBBB's GF Score™ is 35/100, indicating below-average performance in key financial areas.
Is TBBB overvalued or undervalued?
TBBB is currently overvalued, with a GF Value™ estimate of $41.85 compared to its market price of $55.59.
What is TBBB's P/E ratio?
TBBB's current P/E ratio is 311.4x, significantly higher than its 5-year median of 139.6x, indicating that it is trading at an elevated valuation compared to historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
BBB Foods Inc. (NYSE: TBBB - Get Free Report) shares hit a new 52-week high on Monday. The company traded as high as $55.91 and last traded at $55.0550, with a volume of 53,339 shares trading hands. The stock had previously closed at $55.59. Analyst Upgrades and Downgrades TBBB has been the topic of several recent
Can Space Exploration Technologies (SPCX +1.89%) actually become the first company ever to generate $1 trillion in annual sales? Elon Musk thinks so.
SpaceX is growing fast, and it reported $14.6 billion in third-quarter revenue, a 161% year-over-year increase. However, CEO Elon Musk thinks it can grow much, much faster.
"What this implies for SpaceX's annual recurring revenue by the end of 2027 is somewhere between $500 billion and $1 trillion," he said on the Oct. 20 earnings call, referring to the growth of its newly renamed "super intelligence" business.
Let's consider what this could mean for the stock.
SpaceX is growing like wildfire
SpaceX has certainly started off its era as a publicly traded company with a bang. Revenue increased 92% year over year in the second quarter and 161% in the third quarter, and it posted its first quarterly net profit of $4.4 billion. There was momentum across its three segments: the rocket launch business, its Starlink satellite broadband, and the super intelligence (SI) unit.
SpaceX had its first revenue-generating Starship mission, and it launched three missions from three different launchpads in under 13 hours. It's expanding its deals with three new NASA International Space Station crew missions, 18 national security space launch missions, and three commercial Starfall missions, in addition to a contract for Starship to deliver a payload to the moon. Revenue increased 84% over last year, and it reported a $7 million loss.
Image source: Getty Images.
Starlink added 1.6 million subscribers in the quarter to bring its total to 13.6 million, and average revenue per user increased 5% to $69 monthly. Revenue was up 69% from last year, and its operating income doubled from $1.2 billion to $2.4 billion. Starlink is now installed on more than 3,800 aircraft, and the service has deals with United Airlines, American Airlines, and many other global carriers.
The major growth, though, is coming from SI, which increased its revenue by 830% year over year. That growth was driven by new cloud computing agreements, the company's acquisition of code-writing AI specialist Cursor, and scaling the Grok AI model's enterprise business.
"We're seeing the fastest growth of a product that I've ever seen in my life for Grok Bot," Musk said in reference to the agentic AI product. The SI segment also produced an operating profit of $431 million, up from a $1.7 billion loss last year.
Reaching for the stars
Musk's goals for SpaceX's future added some sheen to its stellar Q3 report.
"The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle," he said. Starship is meant to be the first such platform, and he expects to demonstrate its full reusability as early as Starship flight 15, which is scheduled for November. The company is also building a new launch base in Louisiana to support an increasing cadence of rocket launches.
SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)
NASDAQ · As of 4:00 PM ET 10/23/26
A large share of SpaceX's launches are dedicated to putting Starlink satellites into orbit, and over the next three years, Musk says he expects to increase the network's bandwidth 100-fold, operating on the order of 100,000 satellites, each one providing more than 10 times the bandwidth of its current models. Five years from now, he expects demand for Starlink's bandwidth to reach 100 times current levels, driven in large part by an explosion in the use of AI agents.
That gets to his biggest goals, which are all in SI. Musk envisions that SI will be faster than all other competitors combined, and he thinks that as Grok Bot continues to scale for enterprises, essentially being able to function as "a virtual human," it will lead to massive growth. That's where his $500 billion to $1 trillion prediction comes in.
Don't discount the risks
If SpaceX reaches even $500 billion in revenue next year, the stock would certainly soar. At today's price, it trades at a lofty 63 times trailing-12-month sales. But if the stock held steady while the top line climbed that far, a year from now, it would be trading at less than 4 times sales. That would be quite a bargain.
But it's necessary to remember that Musk has often set targets and made predictions for his companies that haven't come to fruition. For example, a few years ago, he asserted Tesla was planning to increase its EV deliveries by 50% annually for several years. Last year, deliveries rose by 1%.
There are other risks, too. SpaceX wants to have between 13 and 20 gigawatts of compute power online for the SI business by the end of 2027, and it had less than 2 gigawatts operational as of the end of Q3. Hitting that goal will require heavy spending.SpaceX's capital expenditures in the third quarter came to $19.6 billion -- far exceeding the $14.6 billion in revenue it generated -- and its free cash flow was negative $10 billion.
Following the release of the Q3 report after the close on Oct. 20, SpaceX stock jumped in after-hours trading, but investors should take the company's outlook with a large grain of salt.
Apple (AAPL -0.14%) is one of the greatest businesses we've ever seen. That's indicated by its shares soaring 1,080% in the past 10 years (as of Oct. 21) and its market capitalization of $5 trillion. It is perhaps second to none when it comes to hardware and software design, supporting its position as a powerful consumer brand with loyal customers.
The Cupertino success story is one of the most profitable companies on the face of the planet. Here's why it might be worth $295 a share right now, which represents a 14% discount to the current stock price of $344.
Image source: The Motley Fool.
Pricing power is key to Apple's profitability During the most recent fiscal quarter (third-quarter 2026 ended June 27), the company reported $29.8 billion in net income. That's truly a massive figure. Investors must understand why Apple has built such an extremely lucrative business model.
Credit goes to constant pricing power. Apple's popular devices aren't cheap. But historically, customers have not only shown a willingness to pay up for these products, they tend to upgrade when new iterations come out.
The services segment deserves some attention, too. Last quarter, it represented 28% of the company's revenue, a share that has trended higher over time. Its gross margin of 76% is much better than the 40% that products generate.
Besides the fat margins, what's equally impressive is the durability of the profits. Unlike many of today's artificial intelligence winners, which could end up being one-hit wonders, Apple has been raking it in for a long time. A decade ago, in fiscal 2016, it reported a net margin of 21%. In recent history, this has helped the business produce significant free cash flow that flows to share buybacks and dividends.
AAPL Apple$347.73-$0.50 (-0.14%)
NASDAQ · As of 4:00 PM ET 10/23/26
Shares are currently overvalued The "Magnificent Seven" stock currently trades at 35 times forward earnings estimates. That's certainly an expensive valuation. The S&P 500 index trades at a forward price-to-earnings (P/E) ratio of 19.3, giving Apple a sizable premium of 81%. Value investors might turn away from this business.
There are two sides to the story here. I think it's very easy to argue, based on the forward P/E multiple, that Apple is overvalued right now. The challenge is figuring out what the right multiple should be. Because this is such a high-quality company, maybe a forward P/E ratio of 30 is correct. This implies that the stock is worth $295 right now.
On the other hand, Apple bulls won't hesitate to say that the shares are deserving of a high price tag. This business has certainly earned the market's respect, and there's nothing that says it can't keep producing winning returns in the future.
Some initial public offerings (IPOs) receive a lot of hype, then turn out to be nothingburgers. That isn't the case with Space Exploration Technologies (SPCX +1.89%), better known as SpaceX.
SpaceX's IPO on June 12, 2026, was the biggest in the stock market's history. The stock continues to command the spotlight, with many investors watching its every move.
Nearly five months after its IPO, SpaceX's shares hover near a level close to their IPO price. But where will SpaceX stock trade on the first anniversary of its IPO?
Image source: SpaceX. Image source: SpaceX.
Key developments between now and June 12, 2027SpaceX's share price on June 12, 2027, will depend largely on what happens between now and then. And the company has several key developments on its calendar.
Quarterly earnings reports always have the potential to move stocks. We saw this borne out recently, with SpaceX beating earnings expectations for the third quarter of 2026 while recording lower-than-anticipated capital expenditures. Its stock promptly surged.
Lockup expirations (the end of a period following an IPO when company insiders and early investors are legally allowed to sell their shares on the open market) are another important factor for SpaceX. SpaceX's full 180-day lockup expires on Dec. 8, 2026. Founder Elon Musk will be able to sell his 6.4 billion shares on June 12, 2027.
Musk also revealed that SpaceX and Tesla (TSLA -0.63%) are exploring a merger. To be sure, this isn't a done deal. Musk even stated, "I think some people out there assume that a SpaceX and Tesla merger is a certainty, and I think that would be overstating it."
SpaceX will also be eligible for potential inclusion in the S&P 500 (SNPINDEX:^GSPC) in mid-2027. The key hurdle to joining the index will be demonstrating profitability, which gets us back to those quarterly earnings reports.
SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)
NASDAQ · As of 4:00 PM ET 10/23/26
Three scenarios for SpaceXLet's look at three scenarios for SpaceX over the next year. Each scenario depends on how the previously discussed events unfold.
I think the bull case for SpaceX is that its shares trade between $220 and $240 one year after its IPO. The midpoint of this range reflects an upside of around 50% above the current share price.
For this scenario to play out, SpaceX will need to quickly shake off the negative impact of its lockup expirations. The company will need to continue growing robustly. If SpaceX merges with Tesla, the terms of the deal must be favorable to SpaceX shareholders.
The bear case for SpaceX, in my view, is that the stock trades between $90 and $110 on June 12, 2027. In this scenario, insiders dump their shares in December, creating significant downward pressure on SpaceX's share price. The company doesn't demonstrate a clear path to profitability, thereby delaying its inclusion in the S&P 500. A bungled merger with Tesla could also contribute to the bear case.
What's the base case? As you might expect, it's somewhere in the middle of those two extremes. In this base case scenario, SpaceX's shares are between $165 and $185 by mid-2027. The midpoint of the range is roughly 14% higher than the current share price. For this scenario to happen, SpaceX's growth story and potential Tesla merger are enough to overcome the drag from the lockup expirations -- but not by much.
Wall Street is firmly in the bull camp. The consensus 12-month price target for SpaceX is $240, the high end of my bull case scenario for the stock. Of course, 12 months from now will be several months after SpaceX's IPO anniversary. However, analysts clearly lean more toward the bull case scenario than the base or bear scenarios.
I'm not quite as bullish as Wall Street. However, I think SpaceX could beat the base-case price range. I predict the stock will trade around $200 on June 12, 2027.
As I always do when making a prediction, I will admit that I could be totally dead wrong. There are more uncertainties with SpaceX than with many other stocks.
However, SpaceX could easily be one of the most important companies of the 21st century. Whether I'm right about where the stock will be next year or not, its long-term prospects are exciting.
By You're currently following this author! Click to unsubscribe from email alerts.
Business Insider wants to hear from moms who work for Uber and Lyft. : Jeffrey Greenberg/Universal Images Group via Getty Images Uber and Lyft often talk about the flexibility of working as a driver on their apps.
That aspect of the gig has attracted moms, among other people who often want to earn money outside a 9-to-5 schedule. The job can be appealing to mothers who need to juggle school drop-offs, childcare, and other obligations of parenting.
Others, including single moms, say they feel stuck in ride-hailing work and end up having to drive for Uber or Lyft at set times anyway, depending on when the most passengers need rides.
With costs like childcare and college rising, Uber and Lyft offer some moms a way to make extra money — if they can earn enough on the apps and keep costs like gas and car maintenance under control.
Business Insider wants to speak with moms who drive for Uber, Lyft, or other ride-hailing apps. We want to hear about how you combine the gig with taking care of your kids, including both what's working and what isn't. Please fill out the survey below.
Read next
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Alex Bitter You're currently following this author! Click to unsubscribe from email alerts.
Alex Bitter is a senior retail reporter covering Uber, Lyft, DoorDash, Instacart, and related companies. His coverage ranges from the experiences of gig workers to what's happening inside the world's biggest ride-hailing and delivery companies.Alex has also written about the retail and food industries. Convenience store chain Sheetz ended its "smile policy" after his reporting. Alex lives in the Washington, DC, area, where you can find him studying ancient coins or searching for Civil War artifacts with his metal detector in his free time.Got a tip? Reach out at [email protected] or via encrypted messaging app Signal at +1 (808) 854-4501.
Uber ride-hailing Lyft More Careers Employment Family
Google illegally demolished an estimated 250,000 trees in Finland to make way for a data center, leaving behind a lifeless mud wasteland that forced packs of wolves into a nearby town in search of food and infuriating locals, according to a report.
The tech super giant – continuing its expansion of the booming artificial intelligence industry – cleared 816 acres of woodlands in Northern Finland, The Guardian reported Thursday.
Google is accused of removing the trees and clearing the land before it had full approval — as Finnish law requires companies to complete a mandatory Environmental Impact Assessment before large-scale operations.
Finnish officials, outraged by the mass destruction, suspended all development at two of Google’s data center sites to assess the environmental impact.
An aerial view shows the site where a Google data center is set to be built in Muhos, Finland, on Sept. 29, 2026. AFP via Getty Images
The operation took place outside the rural town of Muhos — southeast of Finland’s fifth-largest city, Oulu — as devastating images of the aftermath captured the vast barren land filled only with tire tracks, muddy puddles and mounds of dirt.
The removal of the large area of trees destroyed the wildlife in the forest, leaving predators like wolves to search for food closer to human developments in the village of Otanmäki, 50 miles from the site.
“We had wolves coming into the village because all the wild animals moved out of the forest,” resident Anni Ranta told the Guardian.
“They fled. What worries me about the data centers is also the noise because this is hard rock soil. Even when we are standing here talking,” she added, comparing the sound to a drum.
Angry residents called out Google, asking for reprieve from the company to help repay for losses the community sustained from previous tech expansions on the land.
“It has been done in the wrong way. American style. No sense. No sense at all,” Muhos resident Antti Jakonen told the outlet, calling on the company to help restore the local salmon population that had been destroyed by hydropower years ago.
The removal of the trees led to water sources flowing near the site to turn brown and pollute the streams. AFP via Getty Images
The site earmarked for Google’s new data center is seen in Vaala, Finland on Sept. 29, 2026. AFP via Getty Images
Ranta revealed she feared the construction of the data centers would be a perfect target for Russian aggression in the already tense European domain.
“I don’t want them in Finland at all. I don’t like the whole idea of AI and the world changing and the way it’s changing. It’s going too fast, too soon.”
Google’s two sites near Muhos and Kajaani, roughly 90 miles apart, are part of its $15 billion investment for AI infrastructure in the Nordic country, which was announced in September.
The Finnish Licensing and Supervision Agency gave Google’s project subsidiary, Tuike Finland Oy, a deadline of Oct. 23 to suspend all operations
“In the opinion of the Finnish Licensing and Supervision Authority, extensive preparatory measures have already been taken in the project areas based on the currently available reports, such as the removal of trees, the stripping of topsoil, the construction of construction site roads and storage areas, changes to ditches and culverts, and stormwater arrangements,” Tommi Muilu, Head of the Environmental Department, said.
“In our opinion, the measures in question will change the environment and cause impacts, the identification and assessment of which are among the key objectives of the EIA procedure,” Muilu said.
Start your day with all you need to know
Morning Report delivers the latest news, videos, photos and more.
Thanks for signing up!
The removal of the trees led to water sources flowing near the site to turn brown and pollute the streams that feed the Oulujoki River.
Google’s Finnish top chief Antti Järvinen claimed the company believed it had legislative approval to commence the large-scale tree cutting.
Järvinen’s explanation was blasted as being “pure arrogance” from the trillion dollar Alphabet company.
“They bought the vast land area and they just started to cut it, just like that,” she said. “It’s pure arrogance and it’s amazing,” Finnish Association for Nature Conservation (SLL) chair Hanna Halmeenpää said, according to the Guardian.
Hanna Halmenpaa, chair of the board of the Finnish Association for Nature Conservation, is pictured near the site where Google’s new data center is set to be built before construction was suspended. AFP via Getty Images
Angry residents called out Google, asking for reprieve from the company to help repay for losses the community sustained from previous tech expansions on the land. AFP via Getty Images
Opponents of the data center believe Google had been rushing to construct the complex before legislation in Finland caught up on AI advancements to implement regulations.
Järvinen apologized for the destruction as the company said it would work to protect water sources before planting back trees around 321 of the acres.
“I wonder why we have to sacrifice so much of our nature. They give everything away too easily,” conservationist Vesa Hyyryläinen told the outlet.
In July, New York Gov. Kathy Hochul signed an executive order, banning all large-scale AI data centers from the state, the first such ban in the US.
The executive order paused new permits for so-called “hyperscale” data centers that looked to use the Empire State’s electrical grid for up to a year.
“I don’t want New York to just be first. I want New York to be first in the right way,” Hochul said at the time.
Netflix (NFLX -1.79%) operates the world's largest streaming platform for movies and television shows, boasting over 325 million paying subscribers. The company isn't growing as quickly as it used to, which is to be expected given its sheer scale, but shareholders are starting to wonder if its best days are officially in the rearview mirror.
Netflix released its operating results for the third quarter of 2026 (ended Sept. 30) on Wednesday, and they didn't do much to squash those concerns. Its stock sank by 6% in after-hours trading, and it's now down by a whopping 51% from last year's record high.
On the bright side, Netflix made some personnel changes that could supercharge its content slate going forward. Plus, its stock is now trading at a bargain valuation, so this might be a great buying opportunity given the company's stellar ability to execute over the long term. Read on.
Image source: The Motley Fool.
Netflix just disappointed investors in one important area
Netflix generated $12.9 billion in revenue during the third quarter, an 11.8% increase from the year-ago period. While the result was in line with expectations, it was the slowest growth rate in three years. But that wasn't the most concerning part.
In late 2022, Netflix launched an affordable subscription tier which is currently priced at $8.99 per month -- significantly below its Standard ($19.99 per month) and Premium ($26.99 per month) tiers. In exchange for the lower price, members have to watch ads, which unlocked an entirely new revenue stream for the company.
The ad-tier subscription consistently accounts for more than half of all new signups in countries where it's available, and in 2025, revenue from selling ad slots to businesses more than doubled to $1.5 billion. Netflix initially predicted it would double again to $3 billion in 2026, but on Wednesday, it revised that forecast down to $2.7 billion. Management said it was because some advertising capabilities are rolling out slower than originally planned, so this might be a temporary blip, but shareholders are worried given the importance of ad revenue to the company's overall growth story.
NFLX Netflix$65.85-$1.20 (-1.79%)
NASDAQ · As of 4:00 PM ET 10/23/26
On a more positive note, Netflix continues to invest in live sporting events which are a major drawcard for new members and also advertisers. The company shows ads to members in every tier during live programming, giving businesses an opportunity to tap into an enormous, highly engaged audience. So far, Netflix is having a lot of success with boxing matches, weekly World Wrestling Entertainment (WWE) events, and National Football League (NFL) and Major League Baseball (MLB) games. Live content is likely to remain a central part of the growth strategy going forward.
Shareholders should have even more confidence in Netflix's future slate following the recent appointment of Peter Rice as chief content officer. He is an industry veteran who previously held senior roles at Walt Disney, 21st Century Fox (which is now owned by Disney), and independent film studio A24. The networks under his leadership aired major live events like the Superbowl, the National Basketball Association (NBA) Finals, the FIFA World Cup, and more.
Rice will now lead Netflix's entire global content organization, overseeing movies, television shows, and live events across every region.
Netflix stock is now trading for a bargain price, so it could be a great long-term buy
Based on Netflix's trailing 12-month earnings of $3.46 per share, its stock is trading at a price-to-earnings (P/E) ratio of 18.5, which is less than half its five-year average of 38.8. Plus, it's cheaper than both the S&P 500 and the technology-heavy Nasdaq-100 indexes, which have P/E ratios of 23.5 and 30.2.
Although Netflix's growth rate is slowing, management says the company has only captured around 7% of its $670 billion opportunity across streaming subscriptions, advertising, gaming, and more. Netflix is in a great position to increase its share in all of those markets, because it's one of the only profitable pure-play streaming companies, so it can continue to outspend its peers to create and license content. This will be a huge competitive advantage over the long term.
Therefore, investors who are willing to hold Netflix stock for a long-term period of 5-to-10 years could do extremely well, especially if they buy it at around the current price.
You are now leaving Barron's websiteBy clicking on the “Proceed” button below, you will be redirected to a third-party website owned and operated by Hong Kong Tiimoot Information Technology Co., Limited. (“HKT”), which is located in Hong Kong. That website operates independently from Barron's and Barron's does not control the website. The privacy practices of HKT are subject to its Privacy Statement, so please read it closely. We are not responsible for HKT's privacy or other data-related practices.
Johnson & Johnson (JNJ.N) on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial.
J&J had gained access to the drug through its $3.05 billion deal to buy Halda Therapeutics last year.
Here are more details:
The company was testing JNJ-6143 in patients with advanced prostate cancer who had received multiple treatments
Its novel approach selectively kills cancer cells by interfering with a protein they need to survive
In the trial, 77% of 31 evaluable patients receiving the 50-milligram dose saw their PSA levels, a blood marker used to monitor prostate cancer, fall by at least 50%; in 48% of patients, PSA levels fell by at least 90%
Among patients whose tumors could be measured using imaging, 69% had a confirmed complete or partial response
"It adds a new mechanism of action to J&J's prostate cancer portfolio," a Johnson & Johnson spokesperson said
Common side effects were nausea and elevated cholesterol and triglyceride levels. One patient discontinued treatment due to adverse effects
The data were presented at the European Society for Medical Oncology Congress
Are you betting on the high-growth volatility of digital assets or the steady cash flow of a global payments giant? Choosing between Coinbase Global (COIN -2.74%) and PayPal (PYPL -0.90%) depends on your appetite for risk.
Coinbase Global serves as a primary bridge to the digital economy, while PayPal remains a titan of traditional digital commerce. Both companies are adapting to a changing landscape where crypto and traditional fiat money increasingly overlap. This comparison analyzes their financials and valuations to help you determine which stock is the better buy.
The case for Coinbase GlobalCoinbase Global operates as a key player for the cryptocurrency economy, representing one of the most prominent fintech stocks in the space. The company generates revenue primarily through transaction fees, with concentrated volume in Bitcoin (BTC -1.26%) and Ethereum (ETH -1.66%) trading pairs. Subscription and services revenue is heavily supported by stablecoin revenue in partnership with Circle Internet Group (CRCL -0.82%), which handles issuance and redemption for its stablecoin USDC (USDC +0.02%).
In FY 2025, revenue reached nearly $7.2 billion, representing roughly 9.4% year-over-year growth. The company reported a net income of approximately $1.3 billion, resulting in a net margin of close to 17.6%. This reflects a change from FY 2024, when revenue was roughly $6.6 billion and net income was nearly $2.6 billion, a period that included significant tax-related adjustments.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.51x. This ratio measures total debt against shareholder equity, showing the company maintains a balanced level of leverage. The current ratio, which measures the ability to pay short-term debts with current assets, is roughly 2.3x. Free cash flow reached nearly $2.4 billion in FY 2025. Note that stock-based compensation (SBC) represented roughly 34.6% of operating cash flow, which inflates reported cash generation since SBC is a non-cash expense added back in the cash flow statement.
The case for PayPalPayPal operates a massive two-sided network that connects roughly 439 million active consumer and merchant accounts globally. It provides a suite of solutions including digital wallets, branded checkout, and peer-to-peer transfers through Venmo and Xoom. The company recently launched an exclusive AI-powered native checkout integration with Glance, aiming to streamline the transaction process for millions of U.S. shoppers.
In FY 2025, revenue reached nearly $33.2 billion, which is a growth rate of approximately 4.3% over the prior year. Net income for the period was roughly $5.2 billion, yielding a net margin of close to 15.8%. This shows a steady upward trend from FY 2024, when revenue was approximately $31.8 billion and net income was roughly $4.1 billion.
According to its December 2025 balance sheet, the debt-to-equity ratio stands at roughly 0.49x. The current ratio is approximately 1.3x, indicating the company has $1.30 in current assets for every dollar of short-term liabilities. Free cash flow for FY 2025 was nearly $5.6 billion, which equals cash from operations minus capital expenditures. This significant cash generation provides the company with flexibility for reinvestment or returning value to shareholders.
Risk profile comparisonCoinbase Global faces significant revenue concentration risk because it depends heavily on volatile asset prices and trading volumes for Bitcoin and Ethereum. However, one key headwind was the regulatory outlook and this has improved considerably. The SEC dismissed its enforcement case against Coinbase in 2025 and has since shifted toward a more crypto-friendly approach, potentially reducing regulatory uncertainty and providing a more favorable environment for the company's long-term growth.
PayPal, meanwhile, faces intense competition from emerging payment platforms and traditional financial institutions. The company also operates under extensive financial regulations, where compliance failures could result in significant penalties. Additionally, its consumer and merchant lending businesses introduce credit risk, particularly during economic downturns when borrowers may struggle to meet their obligations.
Valuation comparisonPayPal offers a significantly lower entry point for investors based on earnings and sales, while Coinbase Global carries a premium for its specialized role in crypto.
MetricCoinbase GlobalPayPalForward P/E55.1x10.7xP/S ratio7.1x1.4xValuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.
The P/S ratio measures the market value of the company relative to its sales over the past twelve months. The Forward P/E ratio compares the current stock price to its future earnings estimates for the next year.
Which stock would I buy in 2026?The financials of these two companies paint very different pictures. Coinbase is growing faster, with revenue increasing more than 9% in 2025 compared to PayPal's roughly 4%. However, PayPal remains the larger and more profitable business, generating nearly four times as much net income and more than twice the free cash flow.
Both companies maintain relatively healthy balance sheets, but valuation is where the differences become particularly striking.
Coinbase Global trades at roughly 55 times expected earnings and seven times annual sales, compared to just 10.7 times earnings and 1.4 times sales for PayPal. Investors are paying a substantial premium for Coinbase Global, largely reflecting expectations for continued growth in the cryptocurrency industry.
That premium could be justified if you believe crypto adoption will accelerate, but it also leaves little room for disappointment.
PayPal, meanwhile, faces challenges of its own. Its customer base has largely stagnated, and competition continues to weigh on its core checkout business. However, growing engagement among existing customers and strong momentum with Venmo suggest the company still has opportunities to expand.
For long-term investors, PayPal looks better here. Its established business, substantial cash generation, and considerably lower valuation offer a more attractive balance of risk and potential reward. PayPal doesn't need explosive growth to justify its current valuation, but it does need to demonstrate that its core business can remain competitive. At today's valuations, that appears safer to me than paying a substantial premium for Coinbase's future growth.
The S&P 500 is full of quality dividend stocks. But is Pfizer (PFE -1.28%) one of them? On the one hand, the drugmaker has one of the highest yields in the index. However, some would point out that Pfizer has faced significant challenges and still has important ones on the horizon. Still, in my view, Pfizer is an attractive income stock to buy and hold. Here's why the dividend is safer than it appears at first.
Recent financial results have exceeded estimates Reduced demand for coronavirus products has affected Pfizer's financial results in recent years. In the second quarter, the company's COVID-19 vaccine, Comirnaty, reported $261 million in sales, down 32% year over year. Pfizer's coronavirus medicine, Paxlovid, performed even worse. The drug posted only $21 million in revenue, down 95% compared to the year-ago period.
Image source: The Motley Fool.
Despite that, Pfizer's total revenue climbed by 3% year over year to about $15 billion. As management has pointed out, the company has exceeded revenue expectations in nine out of the past 10 quarters, and it beat earnings estimates in all 10 of them. True, Pfizer is racing toward important patent cliffs, including that of Eliquis, an anticoagulant, its best-selling medicine.
Eliquis will lose its U.S. patent by the end of the decade. Two other drugs facing patent-exclusivity losses are Ibrance and Xtandi, both of which are cancer drugs. Still, Pfizer's newer and acquired products will help the company overcome this challenge. CEO Albert Bourla noted that these products generate $13 billion in annualized sales and are growing 20% year over year.
Suppose these medicines grow at a compound rate of 15% through the next four years. Their annualized revenue would get to $22.7 billion by 2030. As of the first half of the year, Ibrance, Xtandi, and Eliquis have combined annualized sales of $15.27 billion. That will certainly grow meaningfully before they hit their patent cliffs, and it's not as if their revenue will immediately drop to zero following their loss of patent exclusivity. Does that mean the new (and acquired) products will more than offset the loss-of-exclusivity products? Probably not.
But Pfizer is preparing for this challenge better than some investors realize. We can also look at the work it has done to increase profits. The company eliminated $7.2 billion from its cost base in the past three years. That's a meaningful amount, and future cost-cutting measures could also positively impact the drugmaker's results and help it navigate the difficult period it is entering.
PFE Pfizer$30.03-$0.39 (-1.28%)
NYSE · As of 4:00 PM ET 10/23/26
Pipeline progress is key Is Pfizer's dividend program -- which boasts a juicy 5.8% forward yield -- in trouble as the company faces several patent cliffs? Probably not. Here are two reasons why. First, Pfizer hasn't reduced its dividend in recent years, despite the challenges it has faced. The past isn't a guarantee of the future, but recent history suggests that management prioritizes returning capital to shareholders through dividends.
In the past five years, the company has increased its payouts by 10.26%. That's not extraordinary, but given the challenges it has faced, it's still fairly impressive. Second, beyond recent brand-new approvals, Pfizer boasts a deep pipeline that should help the company significantly expand its lineup of approved products over the next few years.
This is where even stronger growth could come from, especially since Pfizer boasts several highly promising candidates. For instance, the company's investigational long-acting GLP-1 weight-loss medicine, berobenatide, could eventually generate well over $1 billion in sales, given its monthly dosing schedule, strong tolerability, and the predicted rapid growth of the anti-obesity market.
That's just one of the more notable products in Pfizer's pipeline. Of course, the company could face clinical setbacks. But Pfizer's pipeline is deep: It boasts some 16 brand-new products in Phase 3 studies. That's not including earlier-stage programs. Even a modest Phase 3 success rate of 50% -- which is well in line with the industry average -- will lead to a good number of brand-new products over the next few years. These are all good reasons why Pfizer's outlook appears fairly strong, and the dividend looks safe, despite recent headwinds.
Newmont Corporation remains a Hold, with its current valuation reflecting recent portfolio transformation and anticipated project-driven growth. NEM's strategic asset deals, including the Fourmile stake and the significant non-core asset recycling program, position it for long-term Tier 1 production focus. Q3 results exceeded expectations, with $1.9B free cash flow and robust shareholder returns, but near-term cost headwinds and gold price volatility persist.
Palantir (PLTR +0.28%) investors have had a fairly rocky 2026. For most of the year, the stock was losing money. However, starting in August, Palantir reversed the decline and has now gained about 12% for the year. That is roughly in line with the gain for the S&P 500 (^GSPC -0.52%).
However, if you survey the average Palantir investor, almost all of them will say that beating the market is their long-term priority for holding Palantir shares. So, 2026 has been a disappointing year so far. But as long-term investors, there is still plenty of time to deliver strong returns.
So, if you invested $10,000 into Palantir now, what could that be worth by 2030? And will it be good enough to beat the market? Let's take a look.
Image source: The Motley Fool.
Palantir's AI business is booming Palantir originally started off offering its AI platform to government entities. This was an incredibly popular offering, and Palantir's government contracts still make up the majority of its revenue stream today. However, Palantir also expanded to the commercial side of the business, and it's seeing huge adoption of its AI platform.
Essentially, Palantir is an AI platform that plugs into existing data streams and helps derive actionable insights. Through automation, Palantir can also assist in deploying AI agents that do tasks on behalf of its users. Palantir's platform dramatically improves the efficiency of one person in their role and can provide decision-making capabilities that far exceed what a human can deliver.
PLTR Palantir Technologies$196.75+$0.56 (+0.28%)
NASDAQ · As of 4:00 PM ET 10/23/26
Companies and governments are adopting Palantir's software at a breathtaking pace, which is evidenced by its 93% revenue growth rate in Q2. U.S. commercial revenue grew even faster, with revenue from this segment increasing at a 149% pace. AI adoption is happening rapidly, and Palantir is one of the companies that's taking market share.
One of the biggest surprises with Palantir is how great its margins are. New headlines are filled with stories about how quickly some AI firms are growing, but also highlight that they're spending far more than they make. Palantir isn't in that boat, as it delivered an impressive 55% profit margin in Q2.
It doesn't get better than that, but this also opens up a new problem.
Palantir's stock is pricey Palantir's stock is one of the more expensive on the market, and it trades for almost 125 times this year's earnings.
PLTR PE Ratio (Forward) data by YCharts
That's a very pricey stock, and with its profit margin being incredibly high, it can't increase that figure too much to get itself out of this high valuation pickle. Instead, the only path is to grow out of it. Most big tech stocks trade for about 30 times forward earnings, regardless of how fast the business is growing. Take Nvidia (NVDA -0.59%), for example. Its revenue rose 106% in Q2 (faster than Palantir), yet shares trade for 23 times this year's estimated earnings.
So, for Palantir to get to a reasonable 30 times forward earnings valuation, it must quadruple its revenue, which results in its earnings quadrupling as well. That could take a long time, especially considering what Wall Street thinks Palantir's growth rate will be next year. The average Wall Street analyst estimate is that Palantir's revenue will rise 50% during 2027. Palantir has a history of outperforming expectations, so this may be an undershoot. However, if we utilize a 50% growth rate from 2027 to 2030, then it becomes a rather aggressive projection.
Should Palantir's revenue increase at a 50% compounded annual growth rate (CAGR) from 2027 to 2030, that would result in its revenue rising fivefold. That's more than the quadrupling we established above that was required to get Palantir to a reasonable valuation. So, the remaining double could turn a $10,000 investment into about $20,000. That is still market beating-growth, but there are other AI stocks that appear to be in-line for better performance due to a much lower starting valuation.
All of this is because of how expensive Palantir's stock is now. I think this could damp future returns, and it's something that Palantir will have to grow out of.
Being a memory chip stock investor during 2026 has been incredibly rewarding. Two of the best performers are Sandisk (SNDK -1.82%) and Micron Technology (MU +2.46%), and each has delivered impressive returns over the past year. The reason is simple: Memory chip demand is at an all-time high, and supply has run out. Therefore, prices on memory chips have skyrocketed. This has been massively beneficial to Sandisk's and Micron's profit pictures, and each has achieved record margins.
While both stocks are doing quite well, I think there's one clear winner here, and it has far more upside moving forward.
Image source: Getty Images.
Micron and Sandisk are thriving in today's environment
Micron and Sandisk both make memory chips, but the areas they focus on are different. Both Sandisk and Micron make NAND memory, which is used for long-term data storage, often in devices like solid-state drives. Micron also makes DRAM memory, which is used for quick information access in computing devices. Both of these are important, but one segment of Micron's business stands out.
MU Micron Technology$877.55+$21.06 (+2.46%)
NASDAQ · As of 4:00 PM ET 10/23/26
A subsegment of DRAM memory is HBM -- high bandwidth memory. HBM is what is used inside computing units like graphics processing units (GPUs), and Micron points out that industry HBM shipments will grow at a faster pace than conventional DRAM. For 2027 and 2028, Micron expects industry NAND and DRAM shipments to grow in the low to mid-20% range both years. So, there isn't going to be a lot of growth in these two industries, but with HBM growing faster than DRAM, it will give Micron an edge over Sandisk.
Micron also announced an industry-first partnership: a custom HBM chip for Nvidia (NVDA -0.59%). This is a big deal, as Nvidia and its peers were just using off-the-shelf memory chips. But with Micron entering into a partnership with Nvidia, this could lead to a more contractual situation, stabilizing Micron's revenue.
This is an issue for both Sandisk and Micron, as unstable revenue and cash flows are common in the industry. Memory chips are cyclical, and prices can rise and fall with demand. You can see this come to life in Micron's and Sandisk's profit margins, as they are highest when demand is great -- like it is right now.
Data by YCharts.
Both companies are taking steps to mitigate the effects of a downturn by entering into long-term supply agreements with their clients. Basically, Micron and Sandisk are trading the upside of higher memory chip prices for guaranteed revenue. This reduces the ceiling, but also raises the floor of business performance. Since this industry has been plagued by prolonged underperformance due to low demand, this is a smart move. Micron estimates it has now secured about 35% of its revenue through 2030. Sandisk has signed about 50% of its clients to these kinds of contracts.
This is a major evolution for both companies, and it could lead the market to value their stocks higher.
Micron and Sandisk are both cheap
Because the market is expecting a cyclical downturn from both companies at any moment, their stocks don't trade at very high premiums.
Data by YCharts. PE = price-to-earnings.
However, with both companies taking steps to close their cyclical potential, I think they should trade at a nearly average premium for big tech stocks. If they can rally to something like 20 times earnings by the end of their respective fiscal years, that could lead to the stocks tripling or quadrupling in value by this time next year.
That's a huge performance, but that will only occur if the market understands that these two have fundamentally shifted their business to be less exposed to cyclical downturns.
So, which is the winner? I think it's clearly Micron. Micron has exposure to HBM, which will be the highest growth area within the memory chip industry. It's also trading at a far cheaper price tag than Sandisk, giving it more upside. While Sandisk is still a solid pick, Micron offers greater return potential.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Zscaler CEO, chairman and founder Jay Chaudhry joins 'Making Money' to explain why AI is driving the biggest security shift in decades and what consumers need to know.
Vertex Pharmaceuticals Incorporated (VRTX) American Society of Nephrology (ASN) Kidney Week 2026 October 23, 2026 8:15 PM EDT
Company Participants
Susie Lisa - Senior Vice President of Investor Relations
Reshma Kewalramani - CEO, President & Director
Duncan J. McKechnie - Executive VP & Chief Commercial Officer
Conference Call Participants
Dr. Akinlolu Ojo
Richard Lafayette
Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division
Andy Chen - Wolfe Research, LLC
Manoj Eradath - Jefferies LLC, Research Division
Presentation
Susie Lisa
Senior Vice President of Investor Relations
We're going to get started. Thank you very much to everyone here in the room for finding us despite locked doors and escalators and challenging room locations. We really appreciate it. Obviously, a very, very exciting ASN meeting overall, and I think, particularly, for Vertex Pharmaceuticals. So very, very happy that you all can be with us tonight for our kidney program updates at the American Society of Nephrology Kidney Week 2026.
I do just want to go through the agenda briefly. Reshma will kick us off with some remarks about our R&D strategy and our programs, give a quick portfolio overview. Then I have the pleasure of introducing to many of you, I think, for the first time, Dr. Akinlolu Ojo from the University of Kansas, who will discuss the recent AMPLIFIED data and our AMKD program with inaxaplin and then we'll hand it over to Dr. Richard Lafayette, whom you all know well, and he will discuss the data release this morning in the New England Journal of Medicine about povetacicept in IgAN. And then we'll have time for your questions. We'll try and keep it really punchy. We do have a hard stop right at 7:00 p.m. and again, thank you for joining us. Please note that we will be making forward-looking statements, and we ask you to consult all of our SEC filings to discuss the risk factors.
On its third quarter of 2026 earnings call, held on Oct. 22, 2026, Ryder (R +2.02%) raised its full-year 2026 comparable earnings per share forecast range to $14.85 to $15.05. The shift toward contractual asset-light operations provides predictable earnings that protect returns during cyclical downturns. Three things management said stand out.
1. Asset-Light Growth Transforms the Revenue BaseSupply Chain Solutions, which handles warehousing and logistics, and Dedicated Transportation Solutions, which supplies customized vehicle fleets, now drive most of the business. This structural expansion reduces reliance on capital-heavy commercial truck leasing.
Our revenue mix has shifted toward Supply Chain and Dedicated, with approximately 60% of 2026 expected revenue generated by these asset-light businesses, compared to 44% in 2018, as a result of organic growth, strategic acquisitions, and innovative technology.
-- John Diez, Chief Executive Officer2. Cash Generation Unlocks Multibillion-Dollar Capital DeploymentLong-term contractual relationships generate steady operating cash flows and de-lever the balance sheet rapidly. This capital capacity gives management room to balance organic fleet investments with share repurchases and strategic acquisitions.
This leaves around $4.5 billion, which equates to approximately 50% of our quarter end market cap, available for flexible deployment to support growth and return capital to shareholders.
-- Cristy Gallo-Aquino, Executive Vice President and Chief Financial Officer3. Commercial Rental Fleet Signals an Inflection PointFleet Management Solutions, which handles vehicle leasing and maintenance, recorded commercial rental fleet utilization of 77%. Improving spot rates and leaner used vehicle inventories are driving higher transactional demand across tractor classes.
We are seeing good activity on the Industrial side, on the Dedicated sales activity. And then Rental, we did see an acceleration in both tractors and trailers, which is indicative of maybe this freight market showing signs of life, which is one of the encouraging signs we saw in the quarter.
-- John Diez, Chief Executive OfficerLooking AheadFreight conditions show early stabilization as commercial fleet utilization trends higher across core operating units. Ryder's long-term contractual model locks in steady pricing and predictable cash generation across market cycles.
And finally, we are encouraged to see benefits across the business from continued strengthening of freight market conditions. Contractual sales remain strong across all three segments, with activity accelerating in Leased and Dedicated.
-- John Diez, Chief Executive OfficerManagement is tracking rental fleet expansion timing and pricing discipline on contractual renewals. Reduced balance sheet leverage positions the company to capture profitable market share as freight demand recovers.
We continue to outperform prior cycles, and our results are benefiting from consistent execution and the strength of our contractual portfolio. We continue to see significant opportunity for profitable growth, supported by secular trends, our operational expertise, and ongoing momentum from multi-year strategic initiatives.
-- John Diez, Chief Executive OfficerThe Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
On Oct. 20, Space Exploration Technologies (SPCX +1.89%) reported its 2026 third-quarter earnings, posting some impressive numbers.
According to CNBC-tracked analyst estimates, revenue of $14.5 billion easily topped the $12.7 billion expected, and adjusted earnings per share of $0.45 once again beat the $0.13 expected. In addition, SpaceX reported net income of $4.4 billion, a vast improvement over the prior-year net loss of more than $1 billion.
After that report, anyone who hasn't invested in SpaceX yet may be wondering whether they should have bought shares earlier and if it's too late to buy the stock. To answer that question, I'll look at SpaceX's trading history and what's ahead for the company.
Image source: Getty Images.
Get comfortable with price swings SpaceX has only traded publicly since June, but anyone who bought shares and held since then has experienced wild price swings. Shares opened to the public on June 12 at $150 and closed on June 16 at $211.39. After that, however, the stock price was trading as low as $104.83 on Aug. 3.
It then rallied to close at $171.92 on Oct. 6, but it dropped again, closing at $147.79 on Oct. 20. After the Oct. 20 earnings report, however, it opened at $160.56 on Oct. 21.
The point in sharing all that price action is that investing in SpaceX requires a lot of conviction, paired with the ability to handle rapid, steep declines. Without either, it can be easy to have a knee-jerk reaction if the price starts dropping and end up selling for a loss.
SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)
NASDAQ · As of 4:00 PM ET 10/23/26
It's still early Before SpaceX went public, it was viewed as a space company. That's not how it viewed itself, however, as SpaceX listed in its S-1 filing that its total addressable market (TAM) was an ambitious $28.5 trillion, with $26.5 trillion of that coming from opportunities in artificial intelligence (AI).
Its AI division is showing promise, generating $7.6 billion in revenue, up from $813 million in the prior-year period. On top of that, $7.6 billion in AI revenue means the AI division accounted for more than half of SpaceX's $14.5 billion in total revenue.
That said, there's still a long way to go to capture even more of that projected $26.5 trillion TAM. SpaceX could have a first-mover advantage in establishing a new wave of AI infrastructure through space-based data centers, but scaling will take time. It filed an application to launch 1 million satellites into space to serve as data centers, but the earliest those are expected to launch is 2028.
The final verdict on investing in SpaceX Even though the stock price may be climbing after its earnings, as shown from its price history, it's going to go through ups and downs. Also, the company is still in the early stages of pursuing the AI opportunities it believes it has.
Putting that all together, for any investor who plans to hold shares for the long haul and can handle stock price turbulence, it is absolutely not too late to buy SpaceX stock or to invest in an exchange-traded fund that holds it.
ADDIS ABABA, Ethiopia--(BUSINESS WIRE)--Dashen Bank and ShebaMiles have launched a Platinum co-branded Mastercard debit card in Ethiopia, combining secure payments, digital access, loyalty benefits and premium travel privileges in one offering.
Issued by Dashen Bank and powered by Mastercard, the card is linked to Ethiopian Airlines’ ShebaMiles loyalty program. It enables customers to use one card for everyday and travel-related payments while accessing benefits including airport lounge access, airport fast track and global data roaming, in addition to the miles they earn in the air.
The collaboration combines Ethiopian Airlines’ travel network and loyalty program, Dashen Bank’s issuing capabilities, customer reach and Super App, and Mastercard’s global payment network, technology and premium card benefits.
Shehryar Ali, senior vice president and country manager for East Africa and Indian Ocean Islands at Mastercard, said: “Travel is increasingly becoming a connected digital experience, and consumers expect the same level of convenience, security and value from the way they pay. This unique collaboration brings together payments, loyalty and premium travel benefits in a single proposition, creating a differentiated experience for travellers while strengthening Ethiopia’s premium travel payments ecosystem.”
The card will be available in physical and virtual formats. Customers can access the virtual card through the Dashen Bank Super App, which serves more than 2 million active monthly users. Eligible cardholders will also have access to Mastercard Airport Experiences, which provides entry to a global network of more than 1,600 airport lounges.
Ato Asfaw Alemu, CEO of Dashen Bank, said: “Customers today increasingly expect financial services to be more connected, convenient and relevant to the way they live and travel. Our collaboration with Mastercard and Ethiopian Airlines brings together payments, travel and loyalty in a differentiated proposition, while giving customers the flexibility to access their card digitally through the Dashen Bank Super App or through a physical card. This initiative reflects our commitment to delivering innovative, premium financial solutions that enhance the customer experience and create greater value for our customers.”
Ethiopian Airlines serves more destinations within Africa than any other airline. Connecting ShebaMiles with everyday payments and lifestyle benefits creates more opportunities for customers to engage with the airline beyond the flight and is designed to deliver ongoing value for frequent travellers, premium and diaspora customers, and digitally active consumers. It also gives Dashen Bank a differentiated offering for travel-focused customers.
The launch builds on the strategic collaboration between Mastercard and Dashen Bank, including a strategic investment agreement supporting the program’s rollout. Together, Dashen Bank and ShebaMiles are creating a digitally led payment experience that connects travel, loyalty and financial services in Ethiopia, giving customers greater choice, convenience and value throughout their journey.
About Ethiopian
Ethiopian Airlines Group (Ethiopian) is a true African success story, transforming a visionary dream into a globally renowned reality for eight decades. Operating flights to more than 160 domestic and international passenger, and cargo destinations across five continents, Ethiopian bridges the gaps between Africa and the world. Emphasizing passenger comfort and environmental sustainability, Ethiopian utilizes ultra-modern aircraft such as the Boeing 737s, 777s, 787s, Airbus A350-900, A350-1000 and De Havilland Q400.
Ethiopian, the Star Alliance member airline, champions in various coveted awards including Skytrax’s ‘Best Airline in Africa Award’ for eight consecutive years, APEX ‘Best Overall in Africa’ award and ‘Leadership in Connecting Africa through Transport’ Award among others. Ethiopian aims to further excel in its success through a strategic vision and become one of the top 20 most competitive and leading aviation groups in the world. Embracing a Pan-African spirit, Ethiopian is pursuing multi-hub strategy through hubs in Lomé, Togo with ASKY, in Lilongwe, Malawi with Malawi Airlines, in Lusaka, Zambia with Zambia Airways, and in Kinshasa, Democratic Republic of the Congo (DRC) with Air Congo.
For more information, visit our website at www.ethiopianairlines.com email us at [email protected], or call us at (251-11)517-8913/8165/8907.
About Dashen Bank
Headquartered in Addis Ababa, Dashen Bank is one of Ethiopia’s leading private banks and among the country’s most trusted banking brands, with a nationwide network of 900+ branches, 9 dedicated Forex Bureaus, 1,100+ ATMs, and 2,000+ POS terminals. Through its omnichannel banking ecosystem, Dashen provides customers with convenient access to digital payments, banking services, and a wide range of lifestyle and third-party services. At the heart of this digital transformation is the Dashen Bank Super App, Ethiopia’s first banking super app, which brings personal banking, business, and lifestyle solutions together in one secure and seamless platform, serving more than 2 million active monthly users. More at https://dashenbanksc.com/
About Mastercard
Mastercard powers economies and empowers people in 200+ countries and territories worldwide. Together with our customers, we’re building a resilient economy where everyone can prosper. We support a wide range of digital payments choices, making transactions secure, simple, smart and accessible. Our technology and innovation, partnerships and networks combine to deliver a unique set of products and services that help people, businesses and governments realize their greatest potential.
www.mastercard.com/
LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.Investors who lost money on Moderna, Inc. securit.
The AI trade has looked awfully shaky over the last couple of weeks.
CoreWeave, the neocloud company that may have more leveraged exposure to AI than any other company due to its massive debt burden, has plunged in recent weeks on fears over its rising debt yields.
Memory stocks, which include Micron(MU +2.46%), SK Hynix (SKHY +4.05%), Samsung, and Sandisk (SNDK -1.82%), are also seen as some of the riskier AI stocks due to the cyclical nature of memory.
Historically, memory chips have swung from gluts to shortages, with shortages lasting only two to three years on average. SK Hynix just pulled the planned IPO of its flash storage unit in the face of weak stock performance and investor interest, and Micron and its peers are trading down by roughly a third from their peak last July. That sell-off has come even as memory stocks have continued to report blockbuster results, and there's no evidence that the shortage is easing. The jitters seemed to reach a fever pitch earlier this month on fears that new products from China's leading memory chip company would compete with the established giants above.
Nvidia (NVDA -0.59%) CEO Jensen Huang has stepped in to defend the AI sector many times, and now he's doing it with memory. At Nvidia's GTC Berlin conference, Huang said he doesn't expect an oversupply of memory until sometime after 2029, and explained about the supply-demand dynamic, "One of the things that's really great about memory is that you can always use more of it." He added that his company will continue to develop new ways to use memory to accelerate and improve performance.
Jensen Huang. Image source: Nvidia.
Is Jensen Huang right?The value of a stock is supposed to represent the discounted value of future cash flows. In reality, it doesn't often work like that, as it's difficult to accurately predict future cash flows, and investor sentiment often makes stocks swing wildly, as is happening now.
No one knows what the shape of the memory cycle looks like or for how long the shortage will endure. However, it does seem that margins, and therefore prices, are near their peak, which may be a sell signal to some.
Micron reported a gross margin of 86.8% in its most recent quarter, and an operating margin of 80.7%, showing it kept more than four out of every five dollars it brought in in pre-tax profits. Few companies have ever reported an operating margin that high, which gives a sense of how extreme the pricing is in the memory market. For its next quarter, Micron called for a modest decline in gross margin to 85.95%. Realistically, there's probably little room for margins to go higher, and at a certain point, supply is as tight as it's going to get.
The question now is how long the memory market will stay that way, and no one knows the answer.
Is it time to buy memory stocks?Using Micron as an example, I think memory stocks have gotten too cheap given their future profit potential, and the risk/reward profile leans toward long-term demand for memory growing as physical AI products like robotics and self-driving cars come to market.
Micron now trades at a forward P/E of just 5. If it can sustain that level of profits for at least three years, then the valuation seems justified, especially with the potential to spend that cash on share buybacks.
The long-term picture remains uncertain, but if the company can capitalize on the current windfall and approach paying back its valuation in just five years, then the stock is a buy no matter what happens in the 2030s.
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels
Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy
Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients. These data will be shared in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain.
FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells. Sofe-M is an FRα-targeting ADC composed of an Fc-silent, FRα-specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker. The antibody is designed to bind FRα on the surface of tumor cells, delivering exatecan directly into the tumor cell to disrupt DNA replication.
Jacob Van Naarden, Executive Vice President and President of Lilly Oncology: "The standard of care for platinum-sensitive ovarian cancer has remained unchanged for a decade and demands new treatment options. Results for Sofe-M show a promising efficacy and tolerability profile across both platinum-resistant and platinum-sensitive ovarian cancer, regardless of FRα expression levels or prior treatment. These data give us confidence as we continue to study Sofe-M in our Phase 3 FRAmework-01 program to bring this potential new medicine to the women who need it."
The Phase 1 study is evaluating Sofe-M plus bevacizumab in patients with advanced solid tumors, including a cohort of 33 women with PSOC who received Sofe-M (4 mg/kg) plus bevacizumab (15 mg/kg). Patients received a median of three prior systemic regimens (range 1–6), including prior PARPi (67%) and prior bevacizumab (70%). As of the July 6, 2026, data cutoff, the cORR among the 29 patients with measurable disease was 79.3% (23/29; 6 complete responses [CR, 20.7%] and 17 partial responses [PR, 58.6%]), and DCR was 100%. Responses were consistent across FRα expression levels and prior PARPi exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively.
Chrisann Kyi, MD, Gynecologic Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center: "The durable and robust responses we've seen in patients with platinum-sensitive ovarian cancer are important, particularly in a PARPi pretreated population, where the response rate seen with Sofe-M exceeds what has been reported in published platinum re-challenge studies. The observed safety profile and low discontinuation rates, combined with early efficacy results, support the continued investigation of Sofe-M as a potentially meaningful new option for patients."
Sofe-M plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine. No new safety signals were observed. The most common treatment-emergent adverse events (TEAEs) across all patients included epistaxis (73%), nausea (73%), anemia (58%), neutropenia (55%), and fatigue (52%). The most common Grade ≥3 TEAEs were neutropenia (42%) and anemia (24%); febrile neutropenia occurred in 3% of patients, and G-CSF prophylaxis was not mandated. Any-grade neuropathy occurred in 9% of patients, with no Grade ≥3 events. Dose reductions occurred in 42% of patients, and 6% discontinued treatment due to an adverse event.
The FRAmework-01 program is evaluating Sofe-M in three global Phase 3 trials across both platinum-resistant and platinum-sensitive ovarian cancer: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).
For more information on Lilly's oncology pipeline, click here.
Frequently Asked Questions
What is sofetabart mipitecan (Sofe-M)? Sofetabart mipitecan (Sofe-M) is an investigational folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) being studied for the treatment of ovarian cancer and other solid tumors. It is designed to selectively bind to cancer cells expressing FRα and deliver a topoisomerase I inhibitor payload directly to those cells. What is an antibody-drug conjugate? An antibody-drug conjugate (ADC) is a type of medicine that pairs an antibody with a cell-killing payload. The antibody is designed to recognize and bind to a specific protein found on the surface of cancer cells, and the payload is released once the ADC reaches its target, allowing the medicine to attack cancer cells while limiting exposure to healthy tissue.1 How is Sofe-M different from other FRα-targeted ADCs? Sofe-M is designed to target FRα across a broad range of expression levels, including in tumors with lower FRα expression. In this Phase 1 study, Sofe-M plus bevacizumab showed a confirmed objective response rate of 79.3% in platinum-sensitive ovarian cancer (PSOC), with consistent activity across FRα expression levels and regardless of prior PARP inhibitor exposure. Earlier studies in platinum-resistant ovarian cancer (PROC) also demonstrated responses observed across all FRα expression levels and in patients previously treated with mirvetuximab soravtansine (MIRV).2 These results are being further evaluated in Lilly's ongoing Phase 3 FRAmework-01 program, which is studying Sofe-M across both platinum-resistant and platinum-sensitive ovarian cancer. What are the results with sofetabart mipitecan (Sofe-M) in the treatment of platinum-sensitive ovarian cancer (PSOC)?The Phase 1 study demonstrated encouraging clinical activity, including a confirmed objective response rate (cORR) of 79.3% and a disease control rate (DCR) of 100%, in heavily pretreated patients with platinum-sensitive ovarian cancer. Activity was observed across FRα expression levels and regardless of prior PARP inhibitor exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively. Sofetabart mipitecan (Sofe-M) plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine, with no new safety signals observed and a low rate of discontinuation due to adverse events (6%). These findings support continued investigation of Sofe-M in the ongoing Phase 3 FRAmework-01 trial. In this study Sofe-M was dosed at 4 mg/kg. Why is it dosed at 3mg/kg in the Phase 3 FRAmework-01 trial? The 3 mg/kg dose of Sofe-M was selected as the recommended phase 3 dose (RP3D), based on analysis of the safety, efficacy and PK data as monotherapy. The ORR was comparable between the two doses, with ORRs of 59.0% (95% CI 42.1, 74.4) and 58.8% (95% CI 32.9, 81.6), at 4 mg/kg and 3mg/kg doses, respectively. Safety signals were higher at 4 mg/kg versus 3 mg/kg, with Grade ≥3 TRAEs at 56.4% vs 35.3% and dose reductions of 41.0% vs 23.5%. What are historical clinical trial results for standard of care in platinum-sensitive ovarian cancer (PSOC)? For patients who recur after platinum-based chemotherapy and PARP inhibitor (PARPi) maintenance, published real world data on subsequent platinum re-challenge have shown modest response rates, with an objective response rate (ORR) of 41.9%.3 Other studies of platinum-based regimens, such as OCEANS, were conducted prior to the routine use of PARPi maintenance and did not include patients previously treated with a PARPi,4 a population that now represents a majority of patients with recurrent PSOC, including those enrolled in Sofe-M's Phase 1 study. What is platinum-sensitive ovarian cancer (PSOC)? Platinum-sensitive ovarian cancer (PSOC) is characterized as ovarian cancer that comes back more than six months after platinum-based chemotherapy. While people with PSOC can often be treated with platinum again, the disease tends to return, and each recurrence can leave fewer treatment options and shorter remissions.5 What is the current unmet need in platinum-sensitive ovarian cancer (PSOC)? The standard of care for PSOC has remained largely unchanged for more than a decade, even as understanding of which patients benefit from it has evolved. Approximately 50% of PSOC patients have HRD-positive tumors, meaning their tumors carry a specific DNA-repair deficiency.6 These patients tend to have longer progression-free survival with upfront platinum-based chemotherapy plus a PARP inhibitor (PARPi).6 However, when these patients do recur after PARPi maintenance, response rates to subsequent platinum-based treatment are modest.6 Patients with non-HRD-positive tumors see minimal benefit from PARPi to begin with and generally have a poorer prognosis overall.6 Despite these different outcomes between HRD-positive and HRD-negative patients, treatment approaches for PSOC have not meaningfully changed to reflect that distinction. What is the difference between platinum-resistant (PROC) and platinum-sensitive ovarian cancer (PSOC)?The difference comes down to timing. If ovarian cancer returns more than six months after platinum-based chemotherapy, it's considered platinum-sensitive, and patients often respond well to platinum treatment again. If the cancer returns within six months, or continues growing during treatment, it's considered platinum-resistant, and platinum-based chemotherapy is generally no longer effective. Because platinum resistance tends to develop gradually, each recurrence can bring a shorter remission, even while a patient's disease is still classified as platinum-sensitive.6 What is folate receptor alpha (FRα), and why is FRα expression level important in treating ovarian cancer? FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells.7 FRα expression level refers to the amount of the protein present on a tumor and may influence eligibility for or response to certain FRα-targeted therapies.7 How is the FRAmework-01 clinical trial designed? FRAmework-01 is a global, three-part Phase 3 trial studying sofetabart mipitecan (Sofe-M) across both platinum-resistant and platinum-sensitive ovarian cancer in a single program: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The trial's main measure of success across all three parts is how long patients go without their cancer progressing. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Enrollment is ongoing globally with first registrational dose in Q4 2025 for PROC and in Q1 2026 for PSOC.
About Ovarian Cancer
Ovarian cancer is the sixth leading cause of cancer death among women in the United States.8 While most patients initially respond to platinum-based chemotherapy, approximately 70% will experience recurrence, leading to progressively shorter remission periods with each subsequent treatment.6 When cancer recurs during or within six months of platinum therapy, known as platinum-resistant disease, patients face limited treatment options.6,9
About Sofetabart Mipitecan
Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth. FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers. Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 program. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).
About FRAmework-01
FRAmework-01 (NCT07213804) is a Phase 3, randomized, open-label, three-part study evaluating sofetabart mipitecan (Sofe-M; LY4170156) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The primary endpoint is progression-free survival (PFS), assessed by the investigator in Part A and by blinded independent central review (BICR) in Parts B and C. Key secondary endpoints are overall survival, objective response rate, duration of response, and safety. The FRAmework-01 study is in partnership with the European Network for Gynecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).
More information on FRAmework-01 can be found on clinicaltrials.gov.
References
Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8 2. Ray-Coquard, et al. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study, Annals of Oncology (2026), doi: https://doi.org/10.1016/j.annonc.2026.10.001. Romeo M, Gil-Martín M, Gaba L, et al. Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting. Cancers (Basel). 2022;14(18):4414. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045. Lesnock JL, Temin S, Bouberhan S, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. Published online July 13, 2026. doi:10.1200/JCO-26-01591. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi:10.3322/caac.21559. Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353. doi:10.1038/s41416-022-02031-x. American Cancer Society. Cancer Facts for Women. Accessed September 9, 2026. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-women.html. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. doi: 10.1093/annonc/mdz062. About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
MSK Disclosure: Dr. Kyi has financial interests related to Eli Lilly and Company.
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan plus bevacizumab and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Liaquat Ahamed působil jako investiční manažer a má za sebou několik úspěšných titulů zaměřených na historii financí a investování. Na Bloombergu hovořil o své knize 1873, která se zaměřuje na tehdejší investiční boom a následný pád doprovázený finanční krizí. Ta podle něj byla první, o které se dá hovořit jako o globální, protože se týkala USA i Evropy a důsledky byly cítit v celém světě. Jaká poučení toto období přináší?
Na Bloombergu se samozřejmě mluvilo o tom, jak se současné dění kolem umělé inteligence může podobat tomu z roku 1873, respektive z let před tímto zlomem. Ahamed si myslí, že paralel je mnoho. Tehdy i nyní se objevila nová technologie, která v lidech budí nadšení a vyžaduje obrovské investice. Stavba železnic konkrétně vyžadovala investice odpovídající 5 % tehdejšího celkového hrubého produktu Spojených států. Nyní by to odpovídalo asi 1,5 bilionu dolarů ročně. To je částka, která zhruba odpovídá tomu, co plánují investovat hyperscaleři.
Akciový trh byl v roce 1873 mnohem menší. Investiční expanze tak byla financována hlavně dluhovými nástroji. I tím se jí ale současná situace začíná stále více podobat, protože technologické firmy přestávají být schopny financovat investice z vnitřních zdrojů. A obrací se směrem k dluhopisovým trhům. Budování železnic bylo tehdy konkrétně financováno asi z 80 % dluhy. Ty byly hlavním finančním trhem tehdejší doby a dluhopisy železničních společností přispěly k jeho dalšímu růstu a rozvoji.
Ahamed následně hovořil o tom, že do stavby železnic nakonec mířilo příliš mnoho zdrojů a peněz, což snižovalo ziskovost železničních společností. V roce 1872 tak jen jedna z pěti vyplácela dividendu. Na podobný vývoj by si tedy měli investoři dávat pozor i nyní. V „AI bublině“ se podle experta už nacházíme, ale je těžké odhadnout načasování toho, kdy praskne. Ty největší bubliny v minulosti přitom nekončily dobře, „tato by se mezi ně řadila“. Její předzvěstí je klesající ziskovost společností. A také to, že investice jsou už tak obrovské, že způsobují výrazný růst poptávky po kapitálu a následně růst sazeb.
Podobně jako před rokem 1873 i nyní reálné sazby znatelně rostou. A to nejen ve Spojených státech. Jde tedy o globální jev daný tím, že si notně půjčují vlády i soukromé společnosti zaměřující se na umělou inteligenci. Ahamed k tomu zmínil zároveň inflační tlaky, které jsou dalším obvyklým rysem pro období nafukování investiční bubliny. Je totiž větší poptávka nejen po kapitálu, ale i po dalších zdrojích, což se projevuje na jejich cenách a následně inflaci.
V rámci diskuse o poskytování financí a kapitálu odpovídal Ahamed také na dotaz týkající se rodiny Rothschildových, jejíž historii se rovněž věnoval. Podle něj došlo k jejímu posunu mezi „bohatší evropské rodiny“ v době napoleonských válek, kdy se zaměřovala na pašování zboží. A po skončení válek pomáhala ze získaných peněz vládám financovat obnovu hospodářství. Ty totiž trvaly celou generaci a Evropu zanechaly v zuboženém stavu. Rothschildovi se díky tomu dostali „do stejné ligy jako královské rodiny a stali se nejbohatší rodinou na světě“.
